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Abstract 
The prevalence of obesity is growing at an alarming rate worldwide, and current therapies have 
limited benefits. Therefore, it is essential to increase our understanding of the underlying 
mechanisms so that new strategies can be developed to reduce the incidence of obesity related 
diseases. Adiponectin is an adipocyte-derived hormone that regulates glucose and lipid metabolism 
via direct and indirect mechanisms and has anti-inflammatory, anti-diabetic, anti-atherogenic and 
cardioprotective properties. Hypoadiponectinemia is implicated in the aetiology of obesity-related 
diseases making strategies to increase circulating adiponectin levels therapeutically attractive.   
Emerging evidence, predominantly from preclinical studies, suggests induction of 
heme-oxygenase-1 (HO-1) increases adiponectin production concomitant with decreased 
inflammatory tone prompting the proposal of a “HO-1 – adiponectin axis.”  However, the 
underlying mechanisms of increased adiponectin production via HO-1 induction are poorly defined; 
indeed a direct relationship has not been demonstrated. Thus, the overarching aim of this thesis is to 
investigate the effects of HO-1 induction on adiponectin production as well as adipocyte and 
adipose tissue remodelling and metabolic parameters using cellular and mouse models. 
Initial studies were designed to characterize the direct effect of HO-1 induction on adiponectin 
production. We found that treatment with the widely used HO-1 inducer cobalt protoporphyrin 
(CoPP) or hemin for 24-48 h increased HO-1 expression and activity without affecting adiponectin 
expression and secretion, in human mature adipocyte under a variety of experimental scenarios. 
Treatment of adipocytes with TNFα reduced adiponectin production and induced pro-inflammatory 
cytokines production. HO-1 induction failed to reverse these effects. These results do not support a 
direct HO-1 – adiponectin axis. 
However, literature suggests that chronic induction of HO-1 via CoPP administration throughout 
differentiation, promotes adiponectin secretion, albeit in the context of reduced adipogenesis. While 
our previous findings argued against the existence of a direct “HO-1 – adiponectin axis,” they did 
not address the potential effects of chronic induction of HO-1 on adiponectin production. Thus, we 
extended our study to characterise the effects of chronic HO-1 induction throughout differentiation 
of human preadipocytes. In this study we demonstrate that chronic induction of HO-1 with CoPP or 
hemin throughout differentiation results in dose-dependent inhibition of adipogenesis and 
adiponectin production as well as induction of additional NRF2 target genes. Co-treatment with 
SnMP (HO-1 activity inhibitor) and HO-1 siRNA did not prevent these effects. These findings 
suggest that the chronic treatment with CoPP or hemin inhibits adipogenesis and adiponectin 
production potentially by a HO-1-independent mechanism that may be downstream of NRF2. 
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However, our results contradict the majority of reports in the literature. One possibility is that the 
literature that supports “HO-1 – adiponectin axis” used mesenchymal stem cells, thus we propose 
the effect of CoPP is different in different cell types. In fact, recent reports show caloric restriction 
increases adiponectin production from bone marrow adipose tissue but not white adipose tissue 
(WAT) supports our proposal. 
The above findings indicate that induction of HO-1 failed to promote adiponectin production in 
vitro, specifically in WAT. Many studies in pre-clinical models have also shown that CoPP 
administration in obese mice reduces body weight gain, improves insulin sensitivity, reduces 
adipocyte size and attenuates liver steatosis. However, it should be noted that reduction in body 
weight gain which, in-itself, is predicted to decrease adipose tissue as well as systemic 
inflammation and to increase adiponectin. Thus, we again extended our study to characterise the 
effects of administration of CoPP in lean and obese mice. We found that CoPP administration 
significantly increased inflammatory tone in white adipose tissue irrespective of obesity. In obese 
mice, circulating adiponectin levels were elevated by CoPP administration whereas the adiponectin 
gene expression in WAT was significantly reduced. Additional effects specific to obese mice 
included reduced food intake, weight gain, adipocyte size and liver steatosis as well as improved 
insulin responsiveness. Co-administration with SnMP in obese mice ameliorated CoPP effects on 
adipose tissue inflammation and blunted CoPP effects on circulating adiponectin, but not other 
parameters. This supports the hypothesis that the induction of HO-1 may, at least partly, increase 
circulating adiponectin levels. We propose the increase adiponectin production from bone marrow 
adipose tissue (BMAT) may contribute to this, which is consistent with our in vitro findings. Further 
studies are needed to investigate if BMAT plays a central role in the effects of HO-1 induction on 
adiponectin production.  
In summary, the work presented in this thesis establishes CoPP administration in vitro does not 
have benefit on adipocytes, evidence against a direct “HO-1 – adiponectin axis” in WAT. CoPP 
administration in vivo promotes divergent effects on adipose tissue, adiponectin and insulin 
responsiveness. However, the majority of these effects appear to be independent of HO-1 activity. 
These factors suggest there is no positive effect of HO-1 induction on adiponectin production in 
WAT, and emphasize the potential role of BMAT in increased adiponectin production via CoPP 
administration. 
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1.1 Obesity and adipose tissue 
1.1.1 Obesity 
Obesity is defined by the World Health Organization (WHO) as the accumulation of abnormal or 
excessive body fat, resulting in adverse health outcomes[1]. It has been formally recognized as a 
disease by a variety of governments and non-government organizations. The prevalence of 
overweight and obese individuals across populations is measured by BMI (BMI = kg/m2). A BMI 
greater than 25 is considered overweight while greater than 30 is obese[1]. According to the WHO, 
obesity is growing at an alarming rate, and the global obese population has nearly doubled since 
1980[1]. It was reported that more than a quarter of Australian adults are currently obese and 
another 40% are overweight, and this has increased nearly four-fold over the past thirty years [2]. 
Obesity is associated with several chronic diseases such as non-alcoholic fatty liver disease 
(NAFLD) [3], CVD [4], type 2 diabetes [5], cancer [6] and bone metabolic diseases [7]. As more 
health care and ancillary services are needed, and the lost productivity due to obesity-related 
diseases increases, there is a significant increase in health and socio-economic costs. Adipose tissue, 
which plays an important role in obesity, was initially considered a simple fat store organ, but is 
now recognized as a major endocrine organ [8]. Adipose tissue has now moved center stage in 
obesity research, there having been a revolution in our understanding of the biological role 
ofadipose tissue over the past decade. However, we still have limited understanding of the 
underlying mechanisms involved in adipose tissue regulation. Thus, it is important to study adipose 
tissue biology to identifying effective therapeutic strategies. 
 
1.1.2 Adipose Tissue 
There are two types of adipose tissue: white adipose tissue (WAT) and brown adipose tissue (BAT). 
WAT is composed mostly of adipocytes. It also contains a variety of cell types including 
preadipocytes, vascular endothelial cells, fibroblasts and immune cells which make up the stromal 
vascular fraction. It has two main functions; the storage of excess energy and the secretion of 
multiple hormones and cytokines, termed adipokines [9]. BAT were mainly observed in the 
supraclavicular, suprarenal, paravertebral and neck tissues in adults [10, 11]. Mature BAT express 
high levels of uncoupling protein 1 (UCP1), a mitochondrial protein that plays an important role in 
heat production by uncoupling the activity of the respiratory chain from ATP synthesis [11]. The 
activation of BAT contributes to adaptation thermogenesis in response to cold stimulation [12]. It 
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has been reported that WAT can convert to BAT under cold stimulation to produce heat, and these 
adipocytes have been named “brite” or “beige” adipocytes [10]. 
Excess energy is stored in WAT primarily in the form of triglycerides (TG). These TGs are 
mobilized for utilization by other tissues when they require energy [13]. As a consequence of 
chronic positive energy balance, adipose tissue expands. This occurs either by hypertrophy or by 
hyperplasia [14]. Hypertrophy involves increased accretion of lipids within existing adipocytes. 
Hyperplasia is related to the recruitment of stem cells to become preadipocytes, and then 
differentiate to adipocytes for further TG storage. As adipocytes do not proliferate, new 
preadipocytes must be recruited [15, 16]. Preadipocytes undergo cell differentiation to become 
adipocytes, a process termed adipogenesis, which is regulated by several transcription factors such 
as CCAAT/enhancer binding protein (C/EBPs) [17]and peroxisome proliferator-activated receptor 
gamma (PPARγ) [18]. PPARγ has been identified as a dynamic and specific regulator during the 
differentiation of an adipocyte precursor cell into a fully developed adipocyte [19].  
As mentioned previously, WAT was thought to be a passive depot for energy storage for decades, 
but now has been recognized as a major endocrine organ. It secretes a variety of bioactive 
molecules which have profound influence on metabolism and metabolic organs. We call these 
bioactive molecules adipokines, or adipocytokines [13]. Leptin and adiponectin are the two 
adipokines that have been most widely studied and, importantly, are produced predominantly by 
adipocytes. They are currently considered to play a crucial role in metabolism and inflammatory 
processes. However, while WAT has been recognized as an endocrine organ, much less is known 
about the adipokines released by brown and beige fat and their physiological functions. Therefore, 
we mainly investigate WAT in this thesis. 
Leptin is one of the major adipose-derived hormones. It plays an important role in regulating energy 
intake and expenditure, including appetite and hunger, thereby regulating behaviour and 
metabolism. Leptin alters the expression of orexigenic and anorexigenic neuropeptides to regulate 
energy homeostasis by acting primarily in the hypothalamus [20]. Thus, mouse models lacking the 
gene encoding leptin and/or its receptor display a severe obese phenotype and are characterized by 
an increase in food intake and a decrease in energy expenditure [21, 22]. This phenotype can be 
reversed by increasing leptin signalling. In humans, serum leptin concentrations positively correlate 
with percentage of body fat [23]. Leptin deficiency results in obesity and insulin resistance [24], 
whereas recombinant leptin treatment reduces obesity and improves metabolism [25, 26]. Therefore, 
increasing leptin levels may reduce inflammation-related diseases such as CVD, hypertension and 
metabolic syndrome [27]. While high levels of leptin are found in overweight and obese individuals, 
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the anorexigenic signal to the brain does not function. This phenomenon is called leptin resistance. 
Due to the existence of leptin resistance, leptin may not be an effective therapeutic treatment. 
Adiponectin is another major adipose-derived hormone which plays a key role in the regulation of 
glucose and lipid metabolism. Adiponectin is the most abundant adipokine in the circulation  with 
many protective properties, including insulin-sensitization, anti-atherogenisis, anti-inflammation, 
anti-oxidation and cardioprotection [28]. Decreased serum adiponectin has been observed in obesity 
and its associated diseases [29]. Adiponectin-knockout (KO) mice exhibit diet-induced obesity and 
insulin resistance [30] which is reversed by adiponectin administration [31]. Therefore, 
pharmacological strategies to increase plasma adiponectin levels should be useful in the treatment 
of obesity and its related diseases. The details of adiponectin will be discussed later in this review. 
In addition to leptin and adiponectin, many other adipokines have been identified such as apelin, 
chemerin, interleukin-6 (IL-6), monocyte chemotactic protein-1 (MCP-1), plasminogen activator 
inhibitor-1 (PAI-1), retinol binding protein 4 (RBP4), tumor necrosis factor-alpha (TNFα) and 
visfatin [32-34]. 
 
1.1.3 Adipose Tissue Dysfunction 
A large body of evidence indicates that adipose tissue dysfunction contributes to the development of 
obesity related diseases including NAFLD, CVD, type 2 diabetes, cancer and bone metabolic 
diseases [35, 36]. Most patients with obesity and its associate diseases have impaired adipose tissue 
function caused by adipocyte hypertrophy, inflammation and hypoxia. It is well-established that 
obesity is associated with low-grade chronic inflammation [37], as a result of altered adipocyte and 
macrophage secretory profile leading to an over production of pro-inflammatory adipokines and a 
decrease in anti-inflammatory adipokines [38]. Thus, “fit” adipocytes are necessary to maintain a 
healthy metabolic status. 
As described previously, adipocyte hypertrophy occurs when excessive TG accumulates within the 
cell. For decades it was believed that the number of adipocytes is set during childhood and 
maintained through adulthood [39], which indicated that adipose tissue expansion is due to 
increases in the size of adipocytes rather than increases in the number of adipocytes. However, 
recent studies show that adipocytes do not have an unlimited capacity for hypertrophy [14, 40]. In 
addition, Spalding et al. demonstrated that up to 10% of adipocytes in humans are renewed every 
year by analysis of 14C (derived from nuclear bomb tests) integrated in adipocyte DNA [39]. 
Collectively these studies suggest that weight gain initially leads to adipocyte hypertrophy, and 
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when surplus energy storage results in maximum adipocyte hypertrophy, continued excess nutrition 
triggers hyperplasia [40, 41]. The differences in adipose tissue cellularity are closely related to 
obesity and its associated diseases. It has been reported that people with larger subcutaneous 
abdominal adipocytes are more likely to experience hyperinsulinemia and be glucose intolerant 
compared with those with similar adipose tissue mass but smaller adipocytes [41-44]. Salans and 
colleagues showed that larger adipocytes displayed a diminished response to insulin, but insulin 
sensitivity was restored after weight loss and a reduction in fat cell size [43]. These data indicate 
that people who become obese mainly through hypertrophy are more susceptible to metabolic 
complications than those who become obese primarily through hyperplasia [42-44]. Therefore, 
inhibiting fat cell enlargement and increasing adipocyte number may provide a novel therapeutic 
strategy to improve obesity and associated diseases (Figure 1.1).   
 
 
Figure 1.1 Schema showing adipocyte size from metabolically unhealthy obese (MUO) and 
metabolically healthy obese (MHO). Adipose tissue expands primarily through an increase in fat 
cell size in MUO individuals. The hypertrophic adipocyte increases pro-inflammatory factors and 
decreases anti-inflammatory adipokines. This promotes the development of metabolic diseases 
including diabetes, CVD, atherosclerosis, hypertension, stroke and cancers.  Adipose tissue 
expands primarily through an increase in fat cell number in MHO individuals. Those newly 
generated small adipocytes are able to secrete balanced pro- and anti-inflammatory adipokines, and 
thus, they can protect MHO individuals from metabolic diseases.    
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Obesity and inflammation are highly interconnected with respect to the development of metabolic 
disease [45]. Moderate increases in circulating inflammatory cytokines and immune cell infiltration 
into adipose tissue has been reported in obesity and its related diseases [46]. Adipose tissue 
macrophages (ATMs), which are now recognized as important mediators of adipose tissue 
dysfunction, contribute to obesity and insulin resistance [47]. There are two types of infiltrating 
macrophages: M1-macrophages which are increased during obesity and secrete pro-inflammatory 
factors such as TNFα and IL-6; and M2-macrophages which secrete anti-inflammatory factors such 
as IL-10 [48]. Lumeng et al. showed that diet-induced obesity can shift the activation state of ATMs 
from M2 to M1 [48]. Hypertrophic adipocyte-derived free fatty acids (FFAs) can also lead to an 
increase in TNFα production by binding to macrophage toll-like receptor-4 (TLR-4) and activate 
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) [49, 50]. In turn, TNFα 
released from macrophages activates human adipocytes to further increase the levels of 
pro-inflammatory factors [51]. Since adiponectin acts as a potential mediator in the inhibition of the 
activity of NF-κB mediated by TLR [52], it is possible that adiponectin levels play a vital role in 
this loop. 
Hypoxia occurs in adipose tissue from obese mice, and this result from adipose tissue 
hypoperfusion caused by the expansion of fat cells to a point exceeding the diffusion limit of 
oxygen [53]. It has been demonstrated that hypoxia, which induces endoplasmic reticulum (ER) 
stress, is partly responsible for the dysregulation of adipokine production. Meanwhile, ER stress 
inhibits the activity of the adiponectin promoter and PPARγ, which leads to increased adiponectin 
mRNA degradation. Thus, a decline in adiponectin is observed in obesity [54]. 
It has been well-established that weight loss and physical activity increase the production of 
anti-inflammatory cytokines (adiponectin and IL-10) and decrease the production of 
pro-inflammatory cytokines (TNFα, leptin and IL-6) in obesity [55]. However, since lifestyle 
interventions have been largely unsuccessful, it is very important to find other clinical strategies to 
reduce obesity and or related diseases. Thus, knowledge that underpins adipose tissue dysfunction 
may provide novel therapeutic targets to reduce obesity related diseases. 
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1.2 Adiponectin 
1.2.1 Overview 
Adiponectin is an adipocyte-derived hormone which was first identified through the analysis of a 
cDNA library from murine, 3T3-L1 adipocytes [56]. Given that the structure of adiponectin is 
similar to complement factor C1q, adiponectin was originally named Acrp30 (adipocyte 
complement-related protein of 30 kDa). Three independent groups identified it and called it AdipoQ, 
apM1and GBP28 respectively [57].  
Adiponectin achieves high concentrations in the human circulation, around 5-30 ug/mL. Circulating 
adiponectin predominantly exists in three forms: trimers, hexamers, and HMW multimers (12-, 
18-mers and larger), the latter being the most metabolically active (Fig 1.2) [58]. Importantly, the 
level of adiponectin is decreased in obese subjects, unlike other adipose tissue-derived proteins 
which are increased with obesity due to increased adipocyte mass [59]. Previous clinical studies 
have shown that plasma adiponectin levels negatively correlate with insulin resistant [60] and body 
weight [61]. In mouse models, adiponectin shows protective properties such as improvement of the 
ability of insulin to suppress hepatic glucose production as a result of decreased tissue TG, and 
suppression of the elevation of plasma FFAs by increased β-oxidation [9, 62, 63]. Thus, adiponectin 
is associated with the majority of obesity-related diseases, including NAFLD, CVD, type 2 diabetes, 
cancer and bone metabolic diseases.  
 
1.2.2 Adiponectin Receptors and Signaling Pathways 
Adiponectin secretes from adipose tissue and causes pleiotropic effects via two 7 transmembrane 
domain receptors, AdipoR1 and AdipoR2 [64, 65]. Adiponectin receptors express in liver, heart, 
muscle, osteoblasts, adipose tissue, pancreas and the brain [66-72]. Evidence suggest that AdipoR1 
and AdipoR2 serve to transduce adiponectin signals; the increase of adiponectin receptors leads to 
the increase of adiponectin binding , signalling and action [73]. Studies have demonstrated that the 
expression of adiponectin receptors appears to be regulated by many factors. It has been shown that 
the expression of AdipoR1 is reduced in the adipose tissue of obese subjects [74]; feeding and 
insulin reduces the expression of both receptors [75, 76]; and fibrates increase the expression of 
both receptors in adipose tissue [77], but not skeletal muscle [78].  
It has been reported that many intracellular kinases were mediated via adiponectin receptors 
including activation of AMP kinase (AMPK), peroxisome-proliferator activated receptor alpha 
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(PPARα) and P38-MAPK kinase in liver, skeletal muscle and endothelial cells [79]. Of these, 
AMPK acts as a major downstream component of adiponectin signaling and it is involved in 
adiponectin-mediated pleiotropic effects [80]. Studies show that the phosphotyrosine domain of a 
leucine zipper motif (APPL1) is binding to both adiponectin receptors and downstream signaling 
molecules [81, 82]. APPL1 is required for adiponectin-mediated activation of AMPK and 
p38-MAPK pathways. APPL1 is also required for adiponectin-regulated, AMPK-dependent 
phosphorylation and modulation of eNOS in humanendothelial cells [83, 84]. Additionally, the 
anti-inflammatory and cytoprotective effects of adiponectin are, at least partly, mediated via 
APPL1-dependent AMPK activation of the phosphatidylinositol 3-kinase (PI3K)-v-akt (Akt) 
signaling pathway [85]. 
In addition to APPL1, other adiponectin receptor interacting proteins have been identified, 
including the receptor for activated protein kinase C1 (RACK1) [86], the regulatory subunit of 
protein kinase CK2 (CK2β) [87], endoplasmic reticulum protein 46 (ERp46) [88] and 
lymphotoxin-β [89]. Of these, binding of lymphotoxin-β to AdipoR1 appears to be involved in 
adiponectin-mediated suppression of NF-κB signaling in endothelial cells [89]. Erp46 has been 
reported to interact specifically with AdipoR1 via non-conserved N-terminal amino acids, and it is 
involved in regulating adiponectin-stimulated AMPK and p38 MAPK phosphorylation [88]. 
However, the roles of these proteins in adiponectin signaling have not been fully defined. 
 
1.2.3 Adiponectin Production  
1.2.3.1 Molecular Structure and Multimerisation of Adiponectin 
Human adiponectin is a member of the complement factor C1q family. It is a 224 amino acid 
protein which is organised into four domains: an amino-terminal signal peptide at the N-terminus; 
followed by a variable region which exhibits no homology to any other known protein; a 
collagenous domain which contributes to the formation of a collagen-triple helix; and a globular 
domain at C-terminus which shares a significant homology with C1q [90, 91]. The structure of the 
globular region has been determined, and shows similarity to TNFα [92]. 
Adiponectin exists in the circulation predominantly in three forms: Trimers and hexamers, termed 
as low molecular weight (LMW) multimers, and larger complexes (12-, 18-mers and larger) 
described as HMW multimers. Adiponectin produced in bacteria was unable to reduce 
hyperglycemia and restore insulin sensitivity in mice [9]. This is most likely due to the inability of 
bacteria to perform hydroxylation of proline residues within the collagenous domain as well as 
other critical post-translational modifications (PTMs), indicating that PTMs play an essential role in 
the multimerization and insulin-sensitizing actions of adiponectin [93]. Cys36 (Cys39 in mouse) is 
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a conserved cysteine residue in the amino-terminal variable region of adiponectin, which is 
responsible for the formation of a disulfide bond that stabilises HMW adiponectin complexes [94, 
95]. Mutation of Cys39 blocks the assembly and secretion of multimers larger than trimers [94]. It 
has been reported that Cys39 is a key site for succination, which disrupts the multimerisation of 
adiponectin and may contribute to reduced circulating adiponectin in diabetics [96]. In addition to 
the formation of disulphide bonds, adiponectin also undergoes hydroxylation and glycosylation [97]. 
Four conserved lysine residues located in the collagenous domain of adiponectin are involved in 
this process [98, 99]. Mutation of these resides significantly attenuates multimerisation and the 
ability of adiponectin to suppress glucose production in hepatocytes [98, 100]. Numerous studies 
have demonstrated that HMW adiponectin multimers play a predominant role in the bioactive 
functions of adiponectin [93]. Type 2 diabetes and related diseases characteristically show a 
reduction in adiponectin glycosylation and a decrease in HMW multimers [101]. Previous clinical 
studies have shown that plasma HMW adiponectin levels negatively correlate with insulin 
resistance, ascribed to the effects of both chronic hyperglycemia and hyperinsulinemia [60], and 
body weight [61]. Pajvani et al. defined SA as a new functional adiponectin index calculated as 
HMW/(HMW + LMW). They found that changes in SA correlated more closely with improvements 
in hepatic insulin sensitivity than changes in total adiponectin levels [102], although it is 
noteworthy that this alone does not demonstrate causality. These data strongly suggest that PTMs of 
adiponectin are critically involved in regulating the formation of HMW multimers, which largely 
contribute to the insulin-sensitizing activity of adiponectin. Understanding the underlying 
mechanism of regulating adiponectin multimerisation and secretion could give rise to an effective 
therapeutic approach for the treatment of metabolic diseases. 
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Figure 1.2 Adiponectin structure.  (A) The four structural domains of adiponectin are shown in 
block form. Cys36 in the variable region of adiponectin is responsible for the formation of a 
disulfide bond and succination. Four conserved lysine residues located in the collagenous domain 
are responsible for hydroxylation and glycosylation. (B) Adiponectin is synthesised from a single 
subunit which goes through multimerisation to form LMW (trimers and hexamers) and HMW 
(12–18-mers) multimers before secretion. Trimers form a ball and stick-like structure. Hexamers 
consist of two trimers arranged in a parallel head-to-head manner and connected by disulphide bond. 
HMW multimers appear to consist mainly of 18-mers, it is synthesized from trimers and hexamers 
and also connected by disulphide bonds. 
 
1.2.3.2 Regulation of Adiponectin Expression and Secretion 
There are many factors that regulate adiponectin secretion at the transcription level and/or 
posttranslational level, including PPARγ, C/EBP, sterol regulatory element binding protein-1c 
(SREBP-1c), forkhead box protein O1 (FoxO1), cAMP response element-binding protein (CREB), 
nuclear factor of activated T-cells (NFAT), TNFα and interleukins.  
PPARγ plays a key role in regulating adiponectin expression and secretion. It has been demonstrated 
that PPARγ receptors are of great importance in the regulation of adipocyte differentiation, insulin 
action and lipid metabolism [103]. PPARγ is expressed in several key target tissues of insulin action 
such as adipose, liver and skeletal muscle [104, 105]. In both the human and rodent adiponectin 
promoter there are putative PPARγ obligatory binding sites, and mutation of these sites lead to a 
reduction in adiponectin expression [103]. Furthermore, thiazolidinediones (TZDs), PPAR agonists, 
markedly stimulate the expression of adiponectin [106]. Oxidative stress has been report to 
contribute to NAFLD. It has been demonstrated that the expression and secretion of TNFα are 
elevated in obese subjects, which is negatively correlated with adiponectin expression and secretion 
[107]. Adiponectin expression in 3T3-L1 cells treated with TNFα is decreased by up to 85% [108]. 
TNFα exerts its strong transcriptional inhibition of adiponectin by suppressing PPARγ activity [109]. 
The mechanism of  TNFα-regulated adiponectin suppression may be via c-Jun N-terminal kinase 
(JNK), which phosphorylates PPARγ and reduces its DNA-binding activity [110]. TNF-α also 
suppresses SREBP-1c, and C/EBP, both of which are considered to be transcriptional inducers of 
adiponectin [111, 112]. 
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In addition to PPARγ and TNFα, there are many other adipogenic transcriptional factors, including 
C/EBP, SREBPs, FoxO1, CREB, and NFAT that regulate adiponectin secretion at the transcription 
and/or posttranslational level [113-118]. 
 
1.2.3.3 Strategies to Increase Adiponectin 
1.2.3.3.1 Thiazolidinediones (TZDs) and Adiponectin 
TZDs, novel insulin-sensitizing agents, seem to offer a useful treatment for the metabolic 
abnormalities encountered in obesity and associated diseases by reducing plasma glucose and 
insulin levels [119]. Recent studies report that TZDs elevate plasma adiponectin levels in both 
humans and rodents [120]. They also increase adiponectin expression and secretion in a 
dose-dependent manner in 3T3-L1 cells [121]. TNFα reduces adiponectin expression and secretion 
from adipocytes but TZDs reverse the inhibitory effect of TNFα on adiponectin [121, 122]. 
Conversely, studies have also shown that adiponectin inhibits the TNFα signaling pathway in 
endothelial cells and reduces TNFα production in macrophages [123-125]. Therefore, TZDs might 
induce adiponectin production via direct effects on the adiponectin promoter in combination with 
antagonism of the negative effects of TNFα on adiponectin production. In addition, TZDs show a 
close relationship with PPARγ, as described previously. Several studies have demonstrated that 
TZDs regulate the expression of many genes involved in glucose and lipid metabolism through 
binding with PPARγ [126, 127]. It has also been reported that treatment of subjects with type 2 
diabetes with TZD for only 21 days is sufficient to increase the ratio of HMW adiponectin/total 
levels, which may contribute to the hepatic insulin-sensitizing effects of TZDs [128]. Taken 
together, these observations suggest that TZDs may act by inducing adiponectin production, 
especially the secretion of HMW adiponectin, and reducing the effect of TNF-α on the adiponectin 
promoter. 
 
1.2.3.3.2 Omega3 Fatty Acids (PUFA) and Adiponectin 
Omega-3 (n-3) long chain polyunsaturated fatty acids (PUFAs), namely DHA (docosahexaenoic 
acid) and EPA (eicosapentaenoic acid), are mainly found in fish oil.  These compounds are 
reported to exert numerous beneficial effects, including improvements in obesity and metabolic 
disease, partially due to the metabolic actions of n-3 PUFAs in adipose tissue [58]. Fernández-Real 
et al. demonstrated that there is a strong correlation between dietary fatty acid intake and plasma 
adiponectin in healthy humans [128]. A small clinical trial has shown that increased n−3 PUFA 
consumption combined with reduced n−6 PUFA consumption has favourable outcomes, including 
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improvement in anti-inflammatory lipid profiles, increased  plasma adiponectin and decreased 
pro-inflammatory TNFα [129]. Studies in cells and animals have also demonstrated that n−3 PUFA 
may increase adiponectin [130]. Dietary supplementation in rats with EPA+DHA from fish oil 
increases plasma concentrations of adiponectin, decreases inflammation and prevents left 
ventricular remodelling and dysfunction without any effect on adiposity [130]. Fish oil feeding in 
mice significantly induces adiponectin expression in epididymal adipose tissue within 24 h in a 
dose-dependent manner, in a PPARγ-dependent and PPARα-independent manner [131]. Itoh et al. 
demonstrated that administration of EPA in genetically obese mice and diet-induced obese mice 
increased serum adiponectin concentrations [132].  EPA could further reverse the 
macrophage-induced decrease of adiponectin from co-cultured adipocytes, indicating that 
EPA-induced adiponectin secretion may, at least in part, be due to the dowregulation of TNFα [132]. 
All these studies provide important insight into the therapeutic potential of n−3 PUFA. Therefore, 
PPAR is a key transcription factor linking dietary intake of FAs and pharmacological agents to 
adiponectin expression and production.  
 
1.2.3.3.3 Vitamin C and Adiponectin 
Vitamin C, also known as ascorbic acid (AA) or simply ascorbate, is an essential nutrient for 
humans. It is unable to be synthesized by humans due to a mutation in the gene encoding the final 
enzyme for vitamin C biosynthesis, so it must be obtained through the diet. Vitamin C is well 
known for its antioxidant property. Accumulation of free radicals results in oxidative stress [133], 
which has a negative effect on CVD, hypertension, chronic inflammatory diseases, diabetes and 
wound healing [134-136]. Vitamin C can act as an effective scavenger of free radicals and other 
reactive oxygen species [137, 138]. 
Epidemiological studies show that one-third of people in the United States experience vitamin C 
deficiency or depletion [139]. A concentration below 11 µM is considered severe vitamin C 
deficiency while between 11 and 28 µM is marginal vitamin C deficiency.  Epidemiological studies 
indicate that vitamin C levels are decreased in states such as obesity and type 2 diabetes [140-143]. 
Perhaps surprisingly then, supplementation studies have generally failed to show beneficial effects 
of vitamin C supplementation on cardiometabolic parameters [144, 145].  However, as discussed 
by Michels and Frei [146], the failure of such trials to demonstrate any positive effects may reflect 
limitations in trial design, most notably the lack of recruitment of a vitamin C deficient cohort that 
may be expected to benefit from vitamin C supplementation [146]. 
Hence, a number of studies have been performed to address the relationship between vitamin C and 
metabolic parameters. It has been reported that vitamin C plays an important role in the formation 
of HMW adiponectin multimers. It has been described previously that the hydroxylation and 
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subsequent glycosylation of four highly conserved lysine residues in adiponectin plays a key role in 
the formation of HMW adiponectin multimers [94, 98]. Adiponectin is a collagen-like protein that 
shares homology with collagen X, VIII and complement protein C1q [147]. Vitamin C is required 
[148] and consumed in the hydroxylation reaction catalysed by lysyl-hydroxylase enzymes (LH1, 
LH2 and LH3) in the biosynthesis of collagen and collagen-like protein complement component 
C1q [149, 150], which suggests that vitamin C plays a key role in ECM remodelling. Our research 
found that treatment of simpson golabi behmel syndrome (SGBS) cells, a human primary 
pre-adipocyte cell line, with vitamin C increased the secretion of HMW adiponectin, but not total 
adiponectin. Co-treatment with TZDs and vitamin C further increased the secretion of HMW 
adiponectin, but not total adiponectin, compared with treatment with TZDs or vitamin C alone. This 
phenomenon was also observed in the absence of TNFα [151]. However, whether vitamin C 
supplementation in deficient individuals can promote HMW adiponectin should be further studied. 
 
1.2.4Adiponectin Function  
1.2.4.1 Adiponectin in Non-alcoholic Fatty Liver Diseases (NAFLD) 
NAFLD includes a broad range of liver damage ranging from simple nonalcoholic steatohepatitis 
(NASH) to fibrosis and cirrhosis complications. It has been recognized as the hepatic manifestation 
of metabolic syndrome, and insulin resistance is closely associated with the pathogenesis of 
NAFLD [152]. Several studies have shown that adiponectin plays an important role in NASH. 
Hypoadiponectinemia is recognized as an early biomarker of NASH and NAFLD and relates to the 
severity of liver damage [3, 153, 154]. Studies show that adiponectin has anti-steatotic, 
anti-inflammatory, anti-fibrotic, and anti-tumor properties in NAFLD. The anti-steatotic property is 
via the activation of AMP-activated protein kinase (AMPK) and peroxisome proliferator-activated 
receptor-alpha (PPAR-α) signalling. AMPK phosphorylation inhibits energy-consuming processes 
and promotes ATP-producing catabolic pathways [155]. PPAR-α regulates hepatic lipogenic gene 
expression and manipulates fatty acid oxidation [156]. Oxidative stress has been reported to 
contribute to NAFLD, and TNFα induces inflammation and apoptosis in the liver under oxidative 
stress [157]. The anti-inflammatory properties of adiponectin are achieved through the induction of 
anti-inflammatory cytokines and the inhibition of NF-κB activity, thereby suppressing the expression 
of TNFα [158, 159]. Additionally, it has been demonstrated that adiponectin attenuates liver fibrosis 
[160], which plays a critical role in the pathophysiology of NAFLD. The transformation of hepatic 
stellate cells (HSC) into myofibroblasts plays a key role in the initiation of the fibrotic process 
during liver damage. Adiponectin can effectively improve this process by upregulating the 
expression and production of BMP-and activin-membrane-bound inhibitor (BAMBI). BAMBI 
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upregulation leads to the suppression of transforming growth factor-β1 (TGF-β1) and connective 
tissue growth factor (CTGF) synthesis [160-162]. In addition, Kamada and colleagues have shown 
that hepatic tumor formation and oxidative stress markers are enhanced in mice lacking adiponectin 
[163]. These results indicate that adiponectin can protect hepatocytes from hepatic steatosis, fibrosis, 
and hepatic tumor formation, and thus, adiponectin might be considered a possible treatment for 
NAFLD. 
 
1.2.4.2 Adiponectin in Cardiovascular Diseases (CVD) 
CVD is related to obesity and other metabolic disorders and is a leading cause of death globally. It 
is well established that adiponectin plays a critical role in coronary heart disease (CHD) [164], 
hypertension [165], and myocardial infarction [166]. Epidemiological studies suggest that low 
levels of plasma adiponectin, especially HMW multimers, may be an independent risk factor for 
CVD [4, 167]. By contrast, a 10-year follow up epidemiology study by Frystyk and colleagues 
showed that higher levels of plasma adiponectin are related to a decreased risk of CHD, which is 
independent of other risk factors such as waist circumference, BMI etc. [4]. Several animal studies 
have showed the cardioprotective effects of adiponectin in mice. The elevation of plasma 
adiponectin by recombinant adiponectin administration significantly attenuates atherosclerosis as 
well as inhibits the expression of vascular cell adhesion molecule-1 and TNFα in apoE knockout 
mice [168]. Adiponectin null mice exhibit a severe cardiac hypertrophy after pressure overload, 
diminished AMPK signalling, and impaired glucose metabolism [169]. Adiponectin deficient mice 
also exhibit increases in myocardial infarct size, apoptosis and expression of TNFα in an 
ischemia/reperfusion myocardium injury model. These morbidities are reversed after adiponectin 
administration [170]. Using cultured cardiomyocytes, Walsh et al. demonstrated that adiponectin 
activates the cyclooxygenase 2 (COX-2) pathway, regulating COX-2-derived PGI2, and conferring 
vasoprotective properties [170]. Mechanistically, the protective actions of adiponectin are partly 
mediated by regulating the levels of nitric oxide (NO) produced from endothelial nitric oxide 
synthase (eNOS) through AMPK-dependent pathways [171, 172]. Furthermore, adiponectin has 
been shown to inhibit TNFα-induced endothelial cell inflammation [124] and suppress the 
proliferation and migration of aortic smooth muscle cells via the inhibition of growth 
factor–stimulated extracellular signal-regulated kinase (ERK) signalling [173].  Taken together, 
these data indicate that adiponectin acts as a multifunctional protector in vascular remodelling, with 
anti-atherogenic and anti-inflammatory properties. 
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1.2.4.3 Adiponectin in Type 2 Diabetes 
Type 2 diabetes mellitus has been defined as a metabolic disorder characterised by hyperglycemia 
with insulin resistance and a relative lack of insulin. Adiponectin is known to have 
insulin-sensitising properties in type 2 diabetes, multiple sclerosis (MS), hypertension, and 
dyslipidaemia [174]. Epidemiological studies have found that there is a close relationship between 
higher adiponectin levels and lower incidence of diabetes [5, 175]. A variety of clinical studies 
show lower adiponectin levels in obese humans compared to lean subjects. Hotta et al. analysed the 
concentration of plasma adiponectin in age- and BMI–matched non-diabetic and type 2 diabetic 
subjects and found decreased plasma adiponectin in diabetes [61]. They also found a severe 
decrease in plasma adiponectin concentration in type 2 diabetic subjects with coronary artery 
disease, which may indicate that adiponectin plays an important role in atherosclerotic vascular 
damage in diabetes [61]. In the study by Weyer et al. plasma adiponectin positively correlates with 
several insulin sensitive parameters. Furthermore, fasting plasma insulin concentration and insulin 
sensitivity are the predominant determinates of adiponectin concentrations, which indicates that 
plasma adiponectin concentration is closely related to insulin resistance and hyperinsulinemia [60]. 
The most compelling evidence to identify the role of adiponectin in insulin resistance is found in the 
adiponectin-deficient mice when fed a HFD. These mice exhibit higher levels of TNFα and a 
reduction in insulin signalling mediated by muscle insulin-receptor substrate 1 (IRS-1)-associated 
phosphatidylinositol 3 kinase (PI3-kinase), which leads to severe diet-induced insulin resistance [31]. 
The hyperglycemia and hyperinsulinemia which occurs in adiponectin-deficient mice can be 
normalised by adiponectin administration. However, despite growing evidence to support the 
relationship between adiponectin and type 2 diabetes, the underlying mechanisms are still largely 
unknown. A recent study by Waki et al. implicated impaired adiponectin multimerisation in the 
development of type 2 diabetes. They found that in hepatocytes, HMW adiponectin is capable of 
activating AMPK, which has been reported to mediate the effects of adiponectin in glucose and 
lipid metabolism [94]. All of the studies on the role of adiponectin in type 2 diabetes and insulin 
resistance suggest that these metabolic disorders are closely associated with decreased levels of 
adiponectin, and the administration of adiponectin may become a potential therapeutic strategy. 
Further studies to understand the underlying mechanisms are necessary. 
 
1.2.4.4 Adiponectin in Cancer 
Recent studies have reported that obesity plays an important role in the development of many 
malignancies [6]. A large body of evidence shows that plasma adiponectin levels are negatively 
correlated with the risk of malignancies which have been linked to obesity and insulin resistance, 
such as breast cancer [176], endometrial cancer [177, 178], leukaemia [179], colon cancer [178], 
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gastric cancer [180] and prostate cancer [181]. Adiponectin exerts its anti-carcinogenic properties in 
different ways. In obesity, hypoadiponectinemia leads to insulin resistance and hyperinsulinemia 
and results in reduced insulin-like growth factor binding protein 1 (IGFBP1) and IGFBP2. 
Consequently bioavailable IGF1 is increased, contributing to carcinogenesis by promoting 
proliferation and inhibiting apoptosis [182]. Yokota et al. found that adiponectin plays a key role in 
regulating hematopoiesis and the immune system, inhibiting B-cell lymphoma 2 (Bcl-2) mediated 
growth and promoting apoptosis in myelomonocyte (leukaemia) cell lines [183]. Adiponectin also 
regulates several signalling pathways including AMPK, PPARγ, and mitogen-activated protein 
kinase (MAPK) in liver and skeletal muscles [184], thereby potentially interfering with 
carcinogenesis through growth inhibition or the promotion of cell death [185]. In summary, studies 
show that adiponectin plays an important inhibitory role in the development of cancer. 
 
1.2.4.5 Adiponectin in Metabolic Bone Diseases 
Bone is a dense connective tissue that supports and protects the body and organs, produces red and 
white blood cells, and serves as an endocrine organ for the regulation of mineral homeostasis. 
Clinical epidemiological studies show a discrepancy in the relationship between plasma adiponectin 
concentration and bone mineral density (BMD). Following adjustment for age, gender and other 
factors known to influence circulating adiponectin levels (smoking, race) the majority of studies [7, 
186-189], but not all [190], shown an inverse relationship between adiponectin and BMD. 
 
In in vitro studies, adiponectin has been reported to promote the differentiation of mesenchymal 
stem cells (MSCs) to preosteoblasts and inhibit differentiation to adipocytes. COX-2 seems to play 
a central role in this process [191]. Lee and colleagues suggested that adiponectin might activate the 
AdipoR1-p38/MAPK/c-Jun cascade, leading to COX-2-induced osteoblast differentiation [191]. 
Meanwhile, Yokota et al. found that adiponectin could suppress the differentiation of MSCs to 
adipocytes by the COX-2 dependent manner [192]. Oshima et al. has reported that adiponectin may 
increase bone mass by inhibiting osteoclastogenesis and activating osteoblastogenesis [193]. 
However, although several studies have suggested that adiponectin plays a role in bone marrow and 
mesenchymal progenitor cell development, the precise link between plasma adiponectin and 
metabolic bone disease still needs to be further studied. 
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1.3 Heme oxygenase 
 
1.3.1 Overview 
HO, a ubiquitously expressed inducible cellular stress protein, serves as a rate-limiting enzyme 
catalysing the oxidative degradation of heme to the bioactive molecules carbon monoxide (CO), 
biliverdin, and ferrous iron. Biliverdin is subsequently converted into bilirubin [194]. The ferrous 
iron is rapidly sequestered by ferritin and either pumped out of the cell by an ATPase pump or 
recycled for heme synthesis [195]. Two main isoforms of HO have been identified, the inducible 
isoform HO-1 and the constitutively expressed isoform HO-2 [195]. HO-1 can be induced by 
several stimuli, such as its substrate heme, heavy metals, inflammation, stress, hypoxia and other 
oxidants [196]. The anti-apoptotic and anti-inflammatory properties of HO-1 are largely due to 
these degradation products [197]. CO is reported to have several beneficial functions including 
relaxation of blood vessels [198], suppression of apoptosis [199], stimulation of blood vessel 
formation [200], and inhibition of pro-inflammatory cytokines [201]. Bilirubin is a potential 
antioxidant, and also inhibits NADP(H) oxidase, subsequently inhibiting superoxide anion 
production [202, 203]. Some, but not all [204] evidence suggest that induction of HO-1 has 
beneficial effects in several disease models including metabolic disorders such as insulin resistance, 
type 2 diabetes and obesity [195].Thus, the subsequent studies tried to identify effective approaches 
to induce HO-1 in human [205-207].  CoPP [208-210] and hemin [208, 211, 212] were used to 
induce HO-1 in cell culture and pre-clinical models in most studies. Unlike CoPP, hemin is the 
derivative of heme which is a HO-1 substrate analog that can serve as both an inducer and a 
substrate for HO-1 [213, 214]. The underlying mechanism for the induction of HO-1 typically 
involves reciprocal regulation of Bach1 and Nrf2 protein stability [213].  Both are basic leucine 
zipper transcription factors and the former represses HO-1 expression whilst the latter promotes its 
expression [213].  Interestingly, bivalent metals other than iron, including Cu, Zn, Sn and Co, are 
able to bind to the porphyrin ring within heme and the HO-specific binding region does not 
discriminate between these different metalloporphyrins [219]. As such, these alternate 
metalloporphyrins bind to and inhibit HO-1 enzyme activity because they are not degraded [220]. 
Hence, metalloporphyrins can induce HO-1 expression and compromise enzyme activity. CoPP is 
widely used to induce HO-1 activity as it is a strong inducer of HO-1 expression and weak inhibitor 
of HO-1 activity. In contrast, SnMP is used as a HO-1 inhibitor because it is a weak inducer of 
HO-1 expression but a strong inhibitor of HO-1 catalytic activity [219]. 
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1.3.3 HO-1 and Obesity 
Accumulating evidence has led to the suggestion that induction of HO-1 via CoPP [209, 210, 215] 
or Hemin [211, 212, 216] has a range of beneficial effects on obesity. For example, chronic HO-1 
induction in obese mice prevents body weight gain, increases the number and decreases the size of 
adipocytes, increases circulating adiponectin levels and decreases circulating pro-inflammatory 
cytokine levels [210, 217]. Studies show that CoPP administration to rats either subcutaneously or 
via intra-cerebroventricular injection led to an initial decrease in food intake of between 60-80%, 
compared with vehicle-treated animals [218-220], and subsequently results showed a 20 to 25% 
reduction of body weight compared with vehicle [218-220], but this reduction in body weight was 
eliminated when co-treated with HO inhibitor [217]. CoPP administration and HO-1 induction via 
other compounds have also been demonstrated to induce weight loss. Treatment with hemin has 
been demonstrated to lower body weight in Zucker diabetic fatty rats [221]. Consistent with 
reduction in food intake and lower body weight, insulin sensitivity and glucose tolerance in obese 
mice were also improved [217, 222].  Systemic induction of HO-1 has been reported to lower 
hyperglycemia and hyperinsulinemia in several models of obesity in both rats and mice [217, 221, 
223]. A recent study also showed that MC4R-deficient obese mice treated with long-term (4-23 
weeks of age) CoPP administration, exhibited increased oxygen consumption, and CO2 and heat 
production [224]. Increased adiponectin has also been reported and has been proposed to underpin 
these beneficial effects [209, 225-228]. Studies have also shown that the above benefits can be 
reversed by SnMP treatment [210, 217]. It has also been reported that the beneficial effects of HO-1 
induction are correlated with the increase of phosphorylated AMP-activated protein-kinase (AMPK), 
Akt, insulin receptors and the increase of the glucose transporter-4 in both adipocytes and skeletal 
muscle [223, 224]. Collectively, these results indicate that improvements in basal metabolism 
combined with decreased food intake may underlie the sustained weight loss observed in response 
to HO-1 induction in vivo, and adiponectin seems to be a key element in these beneficial effects of 
HO-1 induction.  However, the underlying mechanism of how the HO-1 inducer affects food 
intake and basal metabolism requires further investigation. 
1.3.4 HO-1 and adipocytes 
Adipose tissue plays an important role in obesity. As individuals become obese, their adipocytes 
enlarge, and adipose tissue undergoes molecular and cellular changes which affect systemic 
metabolism. Pro-inflammatory factors are also increased with the increase of adipose tissue in 
obesity [229]. Recently, emerging studies have reported that chronic induction of HO-1 can 
significantly alter the phenotype of adipocytes [210, 224, 230]. Induction of HO-1 by CoPP or 
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hemin administration in ob/ob mice or Zucker rats reduced adiposity and improved insulin 
sensitivity in diabetic animals [217, 231]. It was first reported by L'Abbate et al that HO-1 induction 
results in increased serum adiponectin in diabetic rats [232]. Subsequent studies showed that 
chronic HO-1 induction appears to remodel adipocytes, resulting in hyperplasia instead of 
hypertrophy [210]. Abraham and colleagues demonstrated that HO-1 induction in adipocytes not 
only leads to an increase in adiponectin, but also a decrease in inflammatory cytokines such as 
TNFα, IL-6, and IL1-β [210, 217, 233]. HO-1 may relieve inflammation by reducing NF-κB, which 
plays an important role in the development of insulin resistance. Moreover, the increased 
phosphorylation of AMPK and PPARγ [234], and decreased levels of monocyte chemoattractant 
protein-1 (MCP-1) [235], may also contribute to the reduced inflammation following HO-1 
induction. As decreased serum adiponectin has been observed in subjects with obesity and its 
associated diseases [29]. Adiponectin-deficient mice exhibit diet-induced obesity and insulin 
resistance [30] which can be reversed by adiponectin administration [31]. Therefore, it is thought 
that the increased levels of adiponectin are the mechanism by which induction of HO-1 results in 
improvement of the health status in obese subjects [217, 225, 227, 236-242].  
 
Figure 1.3 The relationship between HO-1, the adipocyte and adiponectin. HO-1 is the rate 
limiting enzyme that catalyses the degradation of heme into three byproducts: iron, CO and 
biliverdin. Iron is subsequently bound to iron-binding protein ferritin and biliverdin is rapidly 
converted to bilirubin. Adipocytes from obese individuals are usually expanded via hypertrophy. 
These adipocytes usually produce a large amount of pro-inflammatory cytokines, such as TNF-α, 
IL-6, and IL1-β, and a small amount of the beneficial adipokine, adiponectin. HO-1 induction 
remodels adipocytes, resulting in hyperplasia instead of hypertrophy. These adipocytes increase the 
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production of AMPK, PPARγ, and adiponectin, at the same time decreasing the production of 
inflammatory markers and cytokines [209, 210, 215, 243]. 
 
1.3.5 Genetic manipulation of HO-1 
Genetic studies on the increase of HO-1 activity in adipocytes have been performed by two 
independent research groups by using the aP2 promoter to manipulate HO-1 expression in 
adipocytes via lentiviral or transgenic approaches. In the paper published by Cao et al, researchers 
used lentiviral (aP2-HO-1) construct via intracardiac injection, which successfully increased HO-1 
expression in adipose tissue and attenuated high fat diet (HFD) induced body weight increase, 
decreased adiposity and also improved insulin sensitivity and adiponectin production [209]. 
Another paper published by Huang et al, used a classic transgenic approach to increase HO-1 in 
adipose tissue [244]. In contrast to the previous report, this failed to attenuate HFD-induced obesity, 
insulin resistance or the increase in adiponectin. The explanation for these contrasting findings 
needs further investigation, but it is worth know that the aP2 promoter is switched on in the early 
stage of differentiation process, which means the increased HO-1 expression would also be seen in 
immature adipocytes, and it would also drive gene expression in cells other than adipocytes such as 
cardiomyocytes and macrophages [245]. In the papers published by Huang et al, transgenic 
overexpression of HO-1 via the P2 promoter resulted in an increase in HO-1 in peritoneal 
macrophages which is sufficient to increase M2 macrophage polarisation but not enough to protect 
against obesity decreased adiponectin and other metabolic dysfunctions [244].Collectively, these 
studies indicated there may be an association between reduced body weight and improved 
adiponectin levels. Moreover, recent literature published by Jais et al. provided the most 
challenging findings in this area [204]. Jais et al. found that HO-1 acts as a driver rather than a 
brake in obesity associated inflammation. In this study, they found no evidence of a major role for 
HO-1 in adipocyte, muscle or pancreatic β-cells [204]. However, their results indicate that 
inhibition of HO-1, rather than induction, may represent effective therapeutic effects in both 
myeloid and hepatic cells [204]. Due to the discrepancy of these studies, further studies are 
necessary to determine the underlying mechanisms between HO-1, insulin sensitivity, adiposity, 
adiponectin and inflammation.  
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1.3.6 The side effects of metalloporphyrins 
As discussed previously, metalloporphyrins can bind to porphyrin rings to compete for heme and 
inhibit enzyme activity. An exception is CoPP, which is a strong HO-1 inducer, and its HO-1 
synthesis effect outweighs its inhibitory effect [246]. Therefore, the major concern of the use of 
metalloporphyrins is the potential cytotoxicity of heme after blockade of its metabolism. It has been 
reported that metalloporphyrins interact with many heme-containing enzyme systems, including 
soluble guanylyl cylase (sGC), nitric oxide synthase (NOS), and cytochrome P450 (CYP450) [247]. 
They have also been found to affect steroidogenesis, matopoiesis, and the iron status of the body 
[247]. However, the most prominent potential side effect is the photosensitivity of majority 
metalloporphyrins. The photosensitinzing property of metalloporphyrins causes the formation of 
triplet excited states which subsequently causes the formation of singlet oxygen [248]. The excess 
singlet oxygen reacts with many biological substrates, including amino acids, cholesterol and fatty 
acids) [248, 249]. It has been reported that the photophysical parameters and singlet 
oxygen-sensitizing ability of SnMP is strong, and therefore it is expected to have phototoxic effects 
[250]. It has also been reported that mortality was observed in rats when treated with SnMP and 
exposure to cool white fluorescent light simultaneously [251]. The underlying mechanisms are not 
known. Another major concern in the use of metalloporphyrins is that they reduce the CO and free 
iron status of cells; therefore, they may affect hemoproteins and other enzymes. It has been reported 
that SnMP decreases CYP450 activity and therefore affects CYP450-related enzymes of adrenal 
synthesis and drug metabolism in animal models [247]. However, the underlying mechanisms are 
not clear.  
 
 
1.4 Hypothesis and aims 
Adiponectin is an adipose-derived hormone with anti-diabetic, anti-inflammatory and 
cardioprotective properties. Obesity and associated cardiometabolic diseases are characterized by 
reduced adiponectin levels.  Clinical and pre-clinical studies demonstrate the therapeutic value of 
strategies to reverse such “hypoadiponectinemia”.  
HO-1 is a ubiquitously expressed inducible cellular stress protein, which serves as a rate-limiting 
enzyme catalyzing the oxidative degradation of heme. Recently, HO-1 has been reported to have a 
protective effect under conditions of diet-induced obesity with direct effects on adipose tissue. 
Pharmacological induction of HO-1, by CoPP or Hemin, in vivo leads to a reduction in body weight 
and improved insulin sensitivity, increased serum adiponectin and decreased pro-inflammatory 
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cytokines. Subsequent in vitro studies also showed an increase in adiponectin and a decrease in 
pro-inflammatory cytokines following HO-1 induction during differentiation of MSCs. These 
observations have promoted the concept of a HO-1 – adiponectin axis. However, whether such an 
axis represents a direct effect of HO-1 on adiponectin or an indirect effect remains unknown, as do 
the molecular details of the putative HO-1 – adiponectin axis.  
Thus, the aim of this project is to characterize details of the relationship between HO-1, adiponectin 
and metabolic homeostasis in human preadipocytes and in mouse models. 
Hypothesis 1: Induction of HO-1 increases adiponectin production in healthy and TNFα 
treated human adipocytes. 
 Aim 1 - In control and TNFα-treated human SGBS adipocytes, characterise the effects of acute 
(24-48 h) CoPP-induced HO-1 induction on: 
(i) Adiponectin expression (mRNA) and secretion (total and HMW) 
(ii) IL-6 expression and secretion 
(iii) Pro-inflammatory cytokine expression 
(iv) Markers of ER stress 
 Aim 2 - Characterise the effects of chronic CoPP treatment on differentiation of human SGBS 
preadipocytes including determination of: 
(i) Adiponectin expression (mRNA) and secretion (total and HMW) 
(ii) Morphological changes and lipid accumulation during differentiation 
(iii) Temporal mRNA expression profiles of adipogenic markers 
(iv) Basal and insulin-stimulated glucose uptake in ‘mature’ day 14 adipocytes 
 
Hypothesis 2: Induction of HO-1 in vivo alleviates obesity-induced hypoadiponectinemia, 
reduces circulating pro-inflammatory cytokines and improves metabolic function in mice and 
these effects would reverse by SnMP treatment.  
 Aim 3 - Examine the effect of CoPP administration to standard chow diet (SCD) and high fat diet 
fed (HFD) C57BL/6 mice: 
(i) The changes in food intake and body weight  
(ii) Circulating adiponectin profiles (total and HMW) 
(iii) Circulating pro-inflammatory cytokine levels (TNFα, IL-6, MCP-1), glucose and insulin 
levels 
(iv) Adipose tissue architecture, gene expression and macrophage infiltration 
(v) The changes in steatosis and gene expression in liver 
(vi) Insulin and glucose tolerance (via intra-peritoneal insulin tolerance and glucose tolerance 
tests) 
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Aim 4 - Examine the effect of CoPP and CoPP+SnMP administration to HFD C57BL/6 mice: 
(i) The changes in food intake and body weight  
(ii) Circulating adiponectin profiles (total and HMW) 
(iii) Circulating pro-inflammatory cytokine levels (TNFα, IL-6, MCP-1), glucose and insulin 
levels 
(iv) Adipose tissue architecture, gene expression and macrophage infiltration 
(v) The changes in steatosis and gene expression in liver 
(vi) Insulin and glucose tolerance  
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Chapter 2: 
Induction of Heme-oxygenase-1 (HO-1) does 
not enhance adiponectin production in human 
adipocytes: Evidence against a direct HO-1 – 
adiponectin axis 
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2.1 Introduction to this publication 
This Chapter was published as an original article in Molecular and Cellular Endocrinology journal. 
In this study, we demonstrate that in mature human adipocytes: 
• Inducers of HO-1 acutely (24-48 h) increase HO-1 mRNA, protein and activity  
• Acute induction of HO-1 does not enhance or rescue adiponectin production in healthy or 
TNFα-treated cells 
• Acute induction of HO-1 does not ameliorate TNFα-stimulated expression and secretion of 
pro-inflammatory adipocytokines 
Collectively, these findings argue against a direct HO-1 – adiponectin axis and also suggest mature 
adipocytes are unlikely to be acutely involved in mediating the systemic effects of HO-1 induction. 
 
 
Yang, M., Kimura, M., Ng, C., He, J., Keshvari, S, Rose, F. J., Barclay, J. L., Whitehead, J. P., 
Induction of heme-oxygenase-1 (HO-1) does not enhance adiponectin production in human 
adipocytes: Evidence against a direct HO-1 - Adiponectin axis. Mol Cell Endocrinol, 2015. 413: p. 
209-216  
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2.2 Abstract 
Adiponectin is a salutary adipokine and hypoadiponectinemia is implicated in the aetiology of 
obesity-related inflammation and cardiometabolic disease making therapeutic strategies to increase 
adiponectin attractive.  Emerging evidence, predominantly from preclinical studies, suggests 
induction of heme-oxygenase-1 (HO-1) increases adiponectin production and reduces inflammatory 
tone.  Here, we aimed to test whether induction of HO-1 enhanced adiponectin production from 
mature adipocytes.  Treatment of human adipocytes with cobalt protoporphyrin (CoPP) or hemin 
for 24-48 h increased HO-1 expression and activity without affecting adiponectin expression and 
secretion.  Treatment of adipocytes with TNFα reduced adiponectin secretion and increased 
expression and secretion of additional pro-inflammatory cytokines, IL-6 and MCP-1, as well as 
expression of sXBP-1, a marker of ER stress.  HO-1 induction failed to reverse these effects. These 
results demonstrate that induction of HO-1 does not directly enhance adiponectin production or 
ameliorate the pro-inflammatory effects of TNFα and argue against a direct HO-1 – adiponectin 
axis. 
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2.3 Introduction 
Adiponectin is an adipocyte-derived hormone that regulates glucose and lipid metabolism via direct 
and indirect mechanisms and has beneficial anti-inflammatory, anti-diabetic, anti-atherogenic and 
cardioprotective properties [252-255].  Paradoxically, and in contrast to most other 
adipocyte-derived hormones or “adipokines”, circulating adiponectin levels are reduced in obesity 
[256].  Although the precise mechanisms for this reduction are unclear metabolic, oxidative and or 
inflammatory stress are all implicated. The structural complexity of adiponectin appears to be an 
additional factor that makes it particularly sensitive to such cellular stresses [252].  Briefly, 
adiponectin is synthesised as a monomer that undergoes multimerisation to form higher order 
species via a coordinated process that involves a number of post-translational modifications.  
Efficient multimerisation to trimer, hexamer and high molecular weight (HMW) multimers is a 
prerequisite for efficient secretion.  Moreover, functional studies suggest HMW adiponectin is the 
most metabolically active form [257, 258]. Evidence suggests that hypoadiponectinemia contributes 
to the aetiology of obesity-related cardiometabolic diseases and that this typically reflects a 
selective decrease in the circulating levels of HMW adiponectin [252].  Consistent with this, 
numerous pre-clinical and clinical studies demonstrate that reversal of hypoadiponectinemia 
improves a range of cardiometabolic parameters thereby establishing the adiponectin system as an 
attractive therapeutic target [259, 260]. 
Heme oxygenase-1 (HO-1), which is sometimes called heat shock protein 32 (Hsp32), is an 
inducible protein that serves as a rate-limiting enzyme catalysing the oxidative degradation of heme 
to carbon monoxide (CO),  iron and biliverdin, which is subsequently converted to bilirubin [261].  
Each of the products of HO-1 activity modulates various aspects of cellular function and 
homeostasis [261] prompting some to propose HO-1 as a dual purpose “sensor/effector” that both 
senses and responds to oxidative, inflammatory and metabolic stress [207].  Consistent with this 
most, but not all [204], investigators promote the induction of HO-1 as an attractive therapeutic 
strategy to ameliorate the pathophysiology of a range of human diseases including metabolic 
disorders such as insulin resistance, type 2 diabetes and obesity [195, 262].  As such, considerable 
efforts are being made to identify efficacious approaches to induce HO-1 in man [206, 207, 263]. 
Accumulating evidence has led to the suggestion that HO-1 may mediate at least some of its 
beneficial effects by increasing circulating adiponectin levels through what has been termed the 
“HO-1 – adiponectin axis” [217, 225, 227, 230, 239, 241, 264-268].  For example, chronic 
administration of obese mice with the HO-1 inducer cobalt protoporphyrin (CoPP) was reported to 
increase HO-1 protein, prevent weight gain and decrease fat content (in the absence of any change 
in food intake), reduce circulating inflammatory cytokines (including TNFα and IL-6) and increase 
circulating adiponectin levels [217].  Consistent with these changes insulin sensitivity and glucose 
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tolerance were improved in this pre-clinical model thereby providing further evidence of the 
potential therapeutic benefits of HO-1 induction.  Complementary ex vivo studies on isolated bone 
marrow-derived mesenchymal stem cells demonstrated reduced adipogenesis and increased 
adiponectin production upon chronic CoPP treatment in support of a regulatory HO-1 – adiponectin 
axis [217]. 
In spite of the findings detailed above, which typically describe the effects of chronic induction of 
HO-1 on adiponectin levels in vivo or in vitro, to the best of our knowledge no studies have 
examined whether induction of HO-1 has a direct effect on adiponectin production.  Thus, the 
purpose of the present work was to test the hypothesis that acute induction of HO-1 in mature 
adipocytes would increase the production of adiponectin, particularly the more metabolically active 
HMW multimers.  Surprisingly, we found no evidence to support a direct effect of HO-1 on 
adiponectin production (total or HMW), or improvements in markers of cellular stress, in human 
adipocytes in a variety of experimental scenarios.  These results argue against a direct HO-1 – 
adiponectin axis. 
 
 
2.4 Materials and Methods 
 
2.4.1 Reagents and antibodies 
General reagents were obtained from Sigma-Aldrich (Victoria, Australia) and cell culture reagents 
were obtained from Invitrogen (Victoria, Australia) unless otherwise stated. 
 
2.4.2 SGBS cell culture, differentiation and treatment 
Human SGBS preadipocytes, a gift from Martin Wabitsch (University of Ulm, Ulm, Germany) 
[269], were maintained and differentiated in the absence of serum as described [270]. Fully 
differentiated cells (day 14) were treated with increasing concentrations of CoPP (0, 50, 100, and 
150 nM) or Hemin (0, 1, 5 µM), or vehicle, in the presence or absence of TNFα (50 ng/mL). Cells 
and conditioned media were harvested after 24 h or 48 h (following a media change at 24 h for the 
latter).  For experiments performed in the presence of serum, cells were differentiated and 
maintained in media containing 10% FBS and treated with increasing concentrations of CoPP (0, 5, 
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10 µM) in the presence or absence of TNFα (50 ng/mL) on day 14. Cells and conditioned media 
were harvested after 24 h. 
 
2.4.3 Isolation, culture, differentiation and treatment of Primary Human 
Preadipocytes 
Primary human preadipocytes (phPAs) were isolated from subcutaneous adipose tissue from two 
subjects (both female, age 25 & 39 years, BMI 24.1 & 23.3, metabolically healthy - no insulin 
resistance, diabetes or cardiovascular diseases) and cultured independently as described previously 
[270]. The procedure was approved by the Research Ethics Committees of the University of 
Queensland, the Princess Alexandra Hospital, and the Mater Adults Hospital. Both patients had 
given their written informed consent.  Treatments were performed in fully differentiated cells (day 
21) as described above (section 2.2). 
 
2.4.4 Measurement of gene expression by qRT-PCR. 
Gene expression was measured by qRT-PCR and standardized against the expression of cyclophilin 
essentially as previously described [270].  Briefly, total RNA was extracted using Trizol or RNA 
Mini Kit (Ambion Life Technologies, Victoria, Australia) according to the manufacturer’s 
instructions. cDNA was synthesized from 1 μg total RNA using a cDNA synthesis kit (Bioline, 
NSW, Australia) and RT-PCR was performed using the SYBR Hi-ROX kit (Bioline) on a 7900HT 
Fast Real-time PCR system (Ambion Life Technologies).   
Primer sequences were as follows (all human, listed as Forward / Reverse):  Cyclophilin - 
CGCGTCTCCTTTGAGCTGTT / TCTCCAGTGCTCAGAGCACG;   HO-1 - 
CCAGGCAGAGAATGCTGAGTTC / AAGACTGGGCTCTCCTTGTTGC;   ADIPOQ - 
AGAAAGGAGATCCAGGTCTTATTGGT / AACGTAAGTCTCCAATCCCACACT;  IL-6 - 
AGACAGCCACTCACCTCTTCAG / TTCTGCCAGTGCCTCTTTGCTG; TNFα – 
CTCTTCTGCCTGCTGCACTTTG / ATGGGCTACAGGCTTGTCACTC; MCP-1 – 
AGAATCACCAGCAGCAAGTGTCC / TCCTGAACCCACTTCTGCTTGG; sXBP-1 – 
CTGCCAGAGATCGAAAGAAGGC / CTCCTGGTTCTCAACTACAAGGC; BIP – 
CTGTCCAGGCTGGTGTGCTCT / CTTGGTAGGCACCACTGTGTTC; CHOP – 
GGTATGAGGACCTGCAAGAGGT / CTTGTGACCTCTGCTGGTTCTG. 
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2.4.5 Determination of HO-1, Adiponectin and IL-6 protein 
Cellular HO-1 was quantitated in whole cell lysates (in 0.05-0.25 µg protein) using a HO-1 ELISA 
(Life Sciences, Florida, USA).  Secreted total and HMW adiponectin was quantitated using an 
Adiponectin ELISA Kit (ALPCO, New Hampshire, USA and R&D system, Minnesota, USA).  
Absolute secreted total and HMW adiponectin levels are presented for each set of experiments in 
the Figure Legend as mean ± SEM (range: lowest - highest) ng/ml.  Data presented in graphs are 
normalised to values from the control cells (no treatments) which were arbitrarily set at 1. Secreted 
IL-6 was measured in conditioned media (at a 1 in 2 dilution) using an IL-6 ELISA (R&D system, 
Minnesota, USA).   
 
2.4.6 SDS-PAGE/Western blot of ferritin 
SDS-PAGE and Western blotting of cleared whole cell lysates (centrifuged at 2,000 x g for 10 min) 
was performed using standard approaches [271].  Ferritin antibody was from MP Biomedicals, 
(Aurora, Ohio, USA - Catalogue # 65077 - used at 1:2,000) and was followed by an Alexa-800 
conjugated secondary anti-rabbit antibody (Molecular Probes, VIC, Australia – used at 1:20,000) 
and scanned using the LI-COR Odyseey Infrared Imaging System. 
 
2.4.7 Statistical analysis 
Data are presented as mean ± SEM. One-way ANOVA followed by Tukeys was used to test for a 
significant effect of CoPP or hemin in cells incubated without TNFα or independently in cells 
treated with TNFα. When there was no effect of CoPP or hemin a Student t-test (unpaired) was used 
to test for a significant effect of TNFα.  Differences were considered statistically significant at 
p<0.05. Statistical analyses were performed using GraphPad Prism 5.0. 
 
 
2.5 Results 
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2.5.1 Acute CoPP treatment induces HO-1 in a dose-dependent manner in SGBS 
adipocytes 
To investigate whether induction of HO-1 has a direct effect on adiponectin expression or secretion 
we first performed a series of dose response studies in mature (day 14) human SGBS adipocytes to 
identify optimal CoPP concentrations.  We established that treatment with CoPP for 24-48 h at 
concentrations from 50-150 nM was sufficient to promote robust (10-50 fold) induction of HO-1 
mRNA and protein in control cells as well as cells treated with the pro-inflammatory cytokine 
TNFα (Fig 2.1A-D), which compromises adiponectin expression and secretion [151].  Treatment 
of SGBS adipocytes with higher concentrations of CoPP (from 600 nM to 10 µM) failed to promote 
any further significant increase in HO-1 levels, but induced signs of toxicity at concentrations 
greater than 2 µM (data not shown).  Thus, subsequent experiments were performed using CoPP in 
the 50-150 nM range.   
           
Fig 2.1 Acute CoPP treatment (24–48 h) induces HO-1 in a dose-dependent manner in SGBS 
adipocytes. Fully differentiated SGBS adipocytes were incubated with increasing concentrations of 
CoPP (50, 100 and 150 nM) in the absence or presence of TNFα (50 ng/mL) for either 24 or 48 h. 
HO-1 mRNA after treatment for (A) 24 or (B) 48 h. HO-1 protein after treatment for (C) 24 or (D) 
48 h. Values are presented as mean ± SEM of 4 independent experiments and expressed as 
fold-increase over untreated control. ** = p < 0.01, *** = p < 0.001 significant difference compared 
to control. 
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2.5.2 Acute CoPP treatment has no effect on adiponectin production in SGBS 
adipocytes 
Having established that treatment with CoPP for 24-48 h was sufficient to induce HO-1, in the 
absence or presence of TNFα, we then examined the effects of CoPP treatment on adiponectin 
expression and secretion.  There was no significant effect of CoPP treatment on adiponectin 
mRNA levels after 24 or 48 h treatment in either the control or the TNFα treated cells (Fig 2.2A & 
B).  TNFα treatment significantly reduced adiponectin mRNA levels to around 50% of those in 
control cells.  Measurement of secreted total and HMW adiponectin into the conditioned media 
was performed by ELISA.  There was no significant effect of CoPP treatment on total or HMW 
adiponectin secretion after 24 or 48 h treatment in either the control or TNFα treated cells (Fig 
2.2C-F).  TNFα treatment significantly reduced total and HMW adiponectin secretion by around 
40% and 80% at 24 and 48 h respectively.  These results indicate that CoPP has no effect on 
adiponectin mRNA expression or protein secretion in healthy SGBS adipocytes or in TNFα-treated 
adipocytes where adiponectin expression and secretion is significantly compromised. 
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Fig 2.2 CoPP has no effect on adiponectin production in SGBS adipocytes. Fully differentiated 
SGBS adipocytes were incubated with increasing concentrations of CoPP (50, 100 and 150 nM) in 
the absence or the presence of TNFα (50 ng/mL) for either 24 h or 48 h. Adiponectin mRNA after 
treatment for 24 h (A) and 48 h (B). Total adiponectin secretion after treatment for 24 h (C) and 
48 h (D). HMW adiponectin secretion after treatment for 24 h (E) and 48 h (F). Values are 
presented as mean ± SEM of 4 independent experiments and expressed as fold-increase over 
untreated control. ** = p < 0.01, *** = p < 0.001 significant difference compared to non-TNFα 
treated cells. Absolute secreted total/HMW adiponectin concentrations for control cells were: 24 h – 
total 173.5 ± 37.6 (99.1–263.5)/HMW 69.4 ± 23.7 (27.5–137.2): 48 h – total 122.3 ± 43.8 
(33.5–218.0)/HMW 55.9 ± 20.8 (12.3–106.5) ng/ml. 
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2.5.3 Acute CoPP treatment has no effect on pro-inflammatory cytokine production 
in SGBS adipocytes  
Induction of HO-1 has been shown to reduce the circulating levels of pro-inflammatory cytokines 
[238, 272].  To investigate whether HO-1 induction mediated such beneficial effects in SGBS 
adipocytes we examined the effects of CoPP treatment on TNFα-induced IL-6, TNFα and MCP-1 
expression and IL-6 secretion.  TNFα treatment for 24-48 h resulted in a significant increase in 
IL-6 mRNA and secretion (Fig 2.3A-D) as well as TNFα and MCP-1 expression (Fig 2.3E-H). 
However, treatment with CoPP failed to ameliorate the pro-inflammatory effects of TNFα. These 
results indicate that CoPP has no effect on pro-inflammatory cytokine production in healthy SGBS 
adipocytes or in TNFα-treated adipocytes where pro-inflammatory cytokine production is 
significantly increased. 
 
2.5.4 Acute CoPP treatment has no effect on ER stress  
We next went on to investigate the effects of HO-1 induction and TNFα-treatment on markers of 
ER stress.  TNFα treatment resulted in a significant, two-fold increase in sXBP-1 expression and 
this was unaffected by HO-1 induction (Fig 2.4A & B). Treatment with CoPP or TNFα had no 
significant effect on GRP78 (BiP) or CHOP expression (Fig 2.4C-F).  
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Fig 2.3 CoPP does not ameliorate TNFα-stimulated pro-inflammatory cytokine production in 
SGBS adipocytes. Fully differentiated SGBS adipocytes were incubated with increasing 
concentrations of CoPP (50, 100 and 150 nM) in the absence or presence of TNFα (50 ng/mL) for 
either 24 or 48 h. IL-6 mRNA after (A) 24 h and (B) 48 h. IL-6 secretion after (C) 24 and (D) 48 h. 
TNFα mRNA after (E) 24 h and (F) 48 h. MCP-1 mRNA after (G) 24 h and (H) 48 h. Data are 
presented as mean ± SEM of 4 independent experiments and expressed as fold-increase over 
untreated control. *** = p < 0.001 significant difference compared to non-TNFα treated cells. 
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Fig 2.4 CoPP has no effect on markers of ER stress in SGBS adipocytes. Fully differentiated 
SGBS adipocytes were incubated with increasing concentrations of CoPP (50, 100 and 150 nM) in 
the absence or presence of TNFα (50 ng/mL) for either 24 or 48 h. sXBP-1 mRNA after 24 h (A) 
and 48 h (B). BIP mRNA after 24 h (C) and 48 h (D). CHOP mRNA after 24 h (E) and 48 h (F). 
Values are presented as mean ± SEM of 4 independent experiments and expressed as fold-increase 
over untreated control. *** = p < 0.001 significant difference compared to non-TNFα treated cells. 
 
2.5.5 Addition of exogenous substrate does not promote a response to HO-1 
induction in SGBS adipocytes 
The above studies were performed in SGBS adipocytes differentiated and maintained in defined 
medium without serum in accordance with our standard experimental approaches [270, 273, 274].  
Thus, it remained plausible that the lack of any discernible effect of HO-1 induction on adiponectin 
or pro-inflammatory cytokine production may reflect limited substrate availability [213].  To 
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investigate whether this was the case we employed complementary approaches.  First, we 
performed similar experiments in cells treated with hemin, which serves as both inducer and 
substrate of HO-1 [213, 275].  Treatment with hemin at concentrations from 1-5 μM for 48 h was 
necessary and sufficient to promote a 5-10 fold induction in cellular HO-1 protein (Fig 2.5A). 
However, such induction of HO-1 had no effect on adiponectin or IL-6 secretion in control or TNFα 
treated cells (Fig 2.5B & C).  Second, we determined the effects of HO-1 induction with hemin or 
CoPP on ferritin protein levels, which serves as an indirect marker of HO-1 activity [213].  As 
expected, induction of HO-1 with either hemin or CoPP markedly induced the levels of ferritin 
protein (Fig 2.5D & E).  Third, we performed experiments in cells that were differentiated and 
subsequently treated with CoPP in the presence of 10% fetal bovine serum.  Treatment with CoPP 
induced HO-1 (Fig 2.6A), although higher concentrations (5-10 µM) were required to induce HO-1 
to the levels observed following treatment in the absence of serum, probably reflecting 
sequestration of CoPP via binding to serum factors.  TNFα treatment significantly reduced 
adiponectin production and increased IL-6 production, albeit to a lesser extent than was observed in 
the absence of serum.  There was no significant effect of CoPP on adiponectin or IL-6 production 
in either the control or TNFα-treated cells (Fig 2.6B-E).  Collectively, these data indicate that 
induction of HO-1, even in the presence of exogenous substrates, does not affect adiponectin 
production nor reduce the pro-inflammatory effects of TNFα in mature SGBS adipocytes. 
 
 
Fig 2.5 Induction of HO-1 with hemin has no effect on adiponectin or pro-inflammatory 
cytokine production in SGBS adipocytes. Fully differentiated SGBS adipocytes were incubated 
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with increasing concentrations of hemin (1 and 5 μM) in the absence or presence of TNFα 
(50 ng/mL) for 48 h. (A) Cellular HO-1 protein. (B) Secreted total adiponectin. (C) Secreted IL-6. 
Fully differentiated SGBS adipocytes were incubated with hemin (5 μM) or CoPP (150 nM) in the 
absence or presence of TNFα (50 ng/mL) for 48 h. (D) and (E) Cellular ferritin levels. Data are 
presented as mean ± SEM of 4 independent experiments and expressed as fold-increase over 
untreated control. * = p < 0.05, ** = p < 0.01, *** = p < 0.001 significant difference compared to 
control or non-TNFα treated cells. Absolute secreted total adiponectin for control cells was: 
577.3 ± 56 (417.9–663.6) ng/ml. 
          
Fig 2.6 Induction of HO-1 with CoPP has no effect on adiponectin or pro-inflammatory 
cytokine production in SGBS adipocytes in serum. Mature SGBS adipocytes were differentiated 
and maintained in the presence of serum and then incubated with increasing concentrations of CoPP 
(5 and 10 μM) in the absence or the presence of TNFα (50 ng/mL) for 24 h (A) HO-1 mRNA. (B) 
Adiponectin mRNA and (C) Adiponectin (total) secretion. (D) IL-6 mRNA and (E) secretion. Data 
are presented as mean ± SEM of 4 independent experiments and expressed as fold-increase over 
untreated control. * = p < 0.05, ** = p < 0.01, *** = p < 0.001 significant difference compared to 
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control or non-TNFα treated cells. Absolute secreted total adiponectin for control cells was: 
340.8 ± 42.6 (280.6–401.1) ng/ml. 
 
2.5.6 Acute CoPP treatment induces HO-1 in primary human adipocytes but does 
not affect adiponectin and IL-6 production 
Next, to extend our observations from the SGBS adipocytes we performed similar experiments in 
primary human adipocytes treated in the absence and presence of serum.  Treatment with CoPP for 
24 h promoted a dose-dependent increase in HO-1 mRNA and this was comparable in the absence 
or presence of TNFα (Fig 2.7A & B).  Treatment with TNFα significantly reduced adiponectin 
production and increased IL-6 production (Fig 2.7C-J).  Induction of HO-1 with CoPP had no 
impact on adiponectin or IL-6 production in control or TNFα treated cells in either the absence or 
presence of serum (Fig 2.7C-J).  These results are consistent with those from the SGBS adipocytes 
and argue against the existence of a direct HO-1 – adiponectin axis and any major 
anti-inflammatory role for HO-1 in the context of mature human adipocytes. 
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Fig 2.7 Induction of HO-1 with CoPP has no effect on adiponectin or pro-inflammatory 
cytokine production in primary human adipocytes. Primary human adipocytes were 
differentiated in the absence or presence of serum and then incubated in the same with increasing 
concentrations of CoPP (50, 100 and 150 nM in the absence of serum; 5 and 10 μM in the presence 
Mengliu Yang 
52 
 
of serum) in the absence or the presence of TNFα (50 ng/mL) for 24 h. HO-1 mRNA in the (A) 
absence (B) and presence of serum. Adiponectin mRNA in the (C) absence and (D) presence of 
serum. Secreted total adiponectin in the (E) absence and (F) presence of serum. IL-6 mRNA in the 
(G) absence and (H) presence of serum. Secreted IL-6 in the (I) absence and (J) presence of serum. 
Data are presented as mean ± SEM of 2 independent experiments and expressed as fold-increase 
over untreated control. *** = p < 0.001 significant difference compared to control or non-TNFα 
treated cells. Absolute secreted total adiponectin for control cells was: minus serum – 
1143.4 ± 16.7/plus serum – 514.4 ± 14.5 ng/ml. 
 
 
2.6 Discussion 
In the current investigation we aimed to determine whether induction of HO-1 has a direct effect on 
adiponectin production from mature adipocytes, and thereby contribute to the purported HO-1 – 
adiponectin axis.  We could find no evidence to support a direct beneficial effect of HO-1 
induction on adiponectin expression or secretion in healthy or TNFα-treated SGBS or primary 
human adipocytes.  Indeed, despite robust induction of HO-1 mRNA, protein and activity, we 
observed no beneficial effects of HO-1 induction on these parameters or on TNFα-induced ER 
stress or pro-inflammatory adipocytokine production. 
Numerous reports have described an association between pharmacological induction of HO-1 and 
increased circulating levels of the beneficial adipokine adiponectin, in in vivo studies in rodents 
[217, 225, 227, 236-242], and in vitro studies, showing increased adiponectin secretion from 
adipocytes [238, 242].  These observations stimulated the proposal of a HO-1 – adiponectin axis 
[217, 225, 227, 230, 239, 241, 264-268] which could underpin, at least in part, the favourable 
effects of HO-1 induction reported in most pre-clinical models of obesity and related 
cardiometabolic disorders.  Thus, we reasoned information affording a greater understanding of 
the cellular and molecular framework of the HO-1 – adiponectin axis would help to identify, 
validate and progress development of efficacious therapeutic approaches.   
To this end, we performed a series of experiments on mature SGBS and primary human adipocytes 
differentiated in vitro.  Treatments were limited to mature adipocytes in order to reduce the 
potential for confounding effects on the differentiation process, as has been reported by others [238, 
242, 276, 277], and incubation periods were limited to 24-48 h to reduce the likelihood of 
secondary effects.  As expected, treatment with two widely used inducers of HO-1, CoPP and 
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Hemin, resulted in increased HO-1 expression at both the mRNA and protein level.  A 
concomitant increase in HO-1 activity was demonstrated by increased ferritin protein, the levels of 
which are elevated in response to the increase in cellular iron levels [213].   Perhaps surprisingly 
then, we found no evidence of any effect on adiponectin expression, multimerisation or secretion.  
This was the case in healthy control adipocytes as well as adipocytes co-treated with TNFα, a 
pro-inflammatory cytokine implicated in the aetiology of obesity-related cardiometabolic 
dysfunction, known to promote insulin resistance and compromise adiponectin production from 
adipocytes [151].  Furthermore, there was no indication of any impact of HO-1 induction on other 
markers of cellular stress stimulated by TNFα, most notably the induction of other 
pro-inflammatory cytokines including IL-6 and MCP-1 as well as induction of TNFα itself.   
The above findings indicate that acute induction of HO-1 has no direct effect on adiponectin, or 
adipocytokine, production at the level of the mature adipocyte and instead support a model where 
the association between HO-1 induction and increased circulating adiponectin levels most likely 
represents a chronic or indirect effect.  One possibility is that chronic induction of HO-1 may 
increase adiponectin via altering differentiation of preadipocytes.  Consistent with this, in vitro 
studies showed that chronic induction of HO-1, via CoPP administration throughout differentiation, 
promoted increased adiponectin secretion, albeit in the context of reduced adipogenesis [238, 242].  
Whilst it seems somewhat paradoxical that inhibition of adipogenesis would result in increased 
adiponectin secretion, given the dose-dependent effects of chronic CoPP treatment [238] and the 
finding that adiponectin secretion is highest in ‘immature’ adipocytes [278] it remains possible that 
there is an ‘optimal window’ for adiponectin secretion that was somewhat serendipitously 
established in these investigations [238, 242].  In vivo findings showing altered adipose tissue 
architecture consistent with reduced adipocyte hypertrophy and increased adipocyte number appear 
to support such a model, however increased adipogenesis is intrinsically required in such a situation 
[278].  Further investigations are required to establish whether this is the case or whether the 
decrease in adipocyte hypertrophy simply reflects a decrease in body weight (see below).   
Another possibility is that induction of HO-1 may mediate adiponectin production from adipocytes 
indirectly via its effects on other cell types.  For example, a recent report demonstrates that acute 
(24 h) induction of HO-1 via hemin increases adiponectin expression from 3T3-L1 adipocytes 
co-cultured with Raw264.7 macrophages [211].  The inflammatory tone of the co-cultured 3T3-L1 
adipocytes and Raw264.7 macrophages was reduced upon hemin treatment with cellular markers 
suggesting increased levels of M2 macrophage polarisation.  Complementary in vivo investigations 
showed hemin administration reduced adipose tissue inflammation in mice fed a HFD for 2 weeks 
concomitant with reduced markers of M1 macrophage polarisation [211].  A caveat to this and 
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most other in vivo studies is that induction of HO-1 is typically associated with a reduction in body 
weight and/or body weight gain [209, 211, 217, 237, 241, 265, 279, 280] which would, in-itself, be 
predicted to decrease adipose tissue as well as systemic inflammation and to increase adiponectin. 
Genetic attempts to increase the activity of HO-1 specifically in adipocytes have also been 
performed.  Two independent studies used the aP2 promoter to drive expression of HO-1 in 
adipocytes via lentiviral or transgenic approaches.  In the first, intracardial injection of a lentiviral 
(aP2-HO-1) construct resulted in increased expression of HO-1 in adipose tissue and this was 
sufficient to attenuate high fat diet (HFD) induced changes in body weight, associated metabolic 
sequelae and improved adiponectin [209].  In the second, a classic transgenic approach was used 
to increase HO-1 in adipose tissue but, in contrast to the above report, this failed to ameliorate 
HFD-induced obesity, insulin resistance or the decrease in adiponectin [281].  The explanation for 
such contrasting findings remains obscure but may, at least in part, be explained by the different 
methodologies employed to increase HO-1.  It is noteworthy that in both instances expression of 
HO-1 in cells other than mature adipocytes is to be expected as the aP2 promoter is switched on 
early in the differentiation process, meaning immature adipocytes will also express increased HO-1, 
and it also drives gene expression in a range of non-adipocyte cells including cardiomyocytes and 
macrophages [245].  Consistent with the latter, transgenic overexpression of HO-1 by aP2 resulted 
in increased HO-1 in peritoneal macrophages, and, although this was sufficient to affect the 
expression of some M2 markers in the adipose tissue of transgenic mice it was not sufficient to 
protect against obesity, decreased adiponectin and metabolic dysfunction [281].  Taken together 
these studies further highlight the association between reduced body weight and improved 
adiponectin levels.  
Whilst the overwhelming weight of evidence argues in favour of a beneficial effect of HO-1 
induction in the context of cardiometabolic disease there remain a number of elements that demand 
further exploration.  For example, it is unclear what mechanism(s) underpin any observed changes 
in body weight.  Reduced food intake [218, 220] and elevated metabolism, heat production and 
activity [279] have been proposed although, at least in some instances, these changes appear to 
occur in the presence of HO-1 inhibition [280, 282], arguing against a central role for HO-1 activity 
in this context.  However, perhaps the most thought-provoking and challenging work in this area 
comes from the recent, elegant and comprehensive report from Pospisilik, Esterbauer and 
colleagues [204] which continues to put HO-1 centre-stage of obesity and insulin resistance but as a 
driver rather than a brake of obesity-associated inflammation.  In keeping with findings from the 
current study, they found no evidence of a major role for HO-1 in the adipocyte or muscle or 
pancreatic β-cells [204].  However, they presented compelling data to indicate a predominant role 
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for HO-1 in both myeloid and hepatic cells that lead them to propose inhibitors, rather than inducers, 
of HO-1 may represent effective therapeutic agents [204]. 
In summary, in the current report we demonstrate that induction of HO-1 in human adipocytes has 
no direct effect on adiponectin production.  In addition, induction of HO-1 did not ameliorate the 
effects of TNFα on adiponectin or pro-inflammatory adipocytokine production.  These findings 
argue against a direct HO-1 – adiponectin axis and also suggest mature adipocytes are unlikely to be 
acutely involved in mediating the systemic effects of HO-1 induction. 
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Chapter 3: 
Chronic treatment of human preadipocytes with 
CoPP or hemin compromises adipogenesis and 
adiponectin production in a heme-oxygenase-1 
(HO-1) independent manner 
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3.1 Introduction to this publication 
This Chapter was submitted to Scientific report journal. In this study, we demonstrate that in human 
preadipocytes: 
➢ Induction of HO-1 using two commonly-used agents, CoPP or hemin, results in: 
 Dose-dependent inhibition of adipogenesis and adiponectin production as determined  
• Morphologically 
• Genetically 
• Functionally 
 Dose-dependent induction of Nrf2 target genes, NQO1 and GCLM 
➢ Co-treatment with an inhibitor of HO-1 activity, SnMP, or siRNA-mediated knockdown of 
HO-1 fails to ameliorate these effects. 
Collectively, these results demonstrate that chronic treatment of human preadipocytes during 
differentiation impairs adipogenesis and adiponectin production by a mechanism that is independent 
of HO-1. These results do not support the existence of a direct HO-1 – adiponectin axis. 
 
 
Yang, M., Kimura, M., Ng, C., He, J., Barclay, J. L., Whitehead, J. P., Chronic treatment of human 
preadipocytes with CoPP or hemin compromises adipogenesis and adiponectin production in a 
heme-oxygenase-1 (HO-1) independent manner. Scientific report, submitted 
 
 
 
 
 
 
 
Mengliu Yang 
58 
 
Chronic treatment of human preadipocytes with CoPP or hemin 
compromises adipogenesis and adiponectin production in a 
heme-oxygenase-1 (HO-1) independent manner 
 
Mengliu Yang1,2, Masaki Kimura1,3, Choaping Ng1, Jingjing He1, Johanna L. Barclay1, Jonathan P. 
Whitehead1* 
 
1Mater Research Institute-UQ, Translational Research Institute, Brisbane, QLD, Australia 
2Current address, Department of Endocrinology, the Second Affiliated Hospital, Chongqing 
Medical University, 400010 Chongqing, China 
3Current address, Department of Pharmacotherapeutics, Faculty of Pharmacy, Keio University, 
Tokyo, Japan 
 
*Correspondence to: Jon Whitehead, Mater Research Institute-UQ, Translational Research Institute, 
37 Kent Street, Brisbane, QLD 4101, Australia 
Tel 61 07 3343 7633 
Email jon.whitehead@mater.uq.edu.au 
 
 
 
Mengliu Yang 
59 
 
3.2 Abstract 
Adiponectin is an adipocyte derived hormone (adipokine) with a range of beneficial effects.  
Reduced adiponectin is implicated in the aetiology of obesity-related diseases making strategies to 
increase adiponectin production attractive.  Induction of the cellular stress-protein 
heme-oxygenase-1 (HO-1), using agents such as cobalt protoporphyrin (CoPP) or hemin, has been 
reported to increase circulating adiponectin levels and has prompted the proposal of a ‘HO-1 – 
adiponectin axis’.  We previously reported that acute (24-48 h) induction of HO-1 did not enhance 
adiponectin production from mature human adipocytes.  Here, we have extended these studies by 
characterising the effects of chronic HO-1 induction throughout differentiation of human 
preadipocytes.  Induction of HO-1 with CoPP or hemin resulted in dose-dependent inhibition of 
differentiation (adipogenesis) and adiponectin production as well as induction of additional target 
genes of the Nuclear factor erythroid-derived 2-like 2 (NRF2) transcription factor (NQO1 and 
GCLM).  Co-treatment with a HO-1 inhibitor (SnMP) or HO-1 siRNA did not prevent these 
effects.  Collectively, these results suggest chronic treatment with CoPP or hemin inhibits 
adipogenesis and adiponectin production by a HO-1-independent mechanism that may be 
downstream of NRF2.  Furthermore, these results do not support the existence of a direct HO-1 – 
adiponectin axis. 
 
 
 
Keywords: Adipocyte; Differentiation; Obesity; Therapeutic
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3.3 Introduction 
Adiponectin is an important adipocyte derived hormone or ‘adipokine’ that exhibits a range of 
beneficial properties that include anti-inflammatory, cardioprotective and insulin-sensitizing effects 
to reduce cardiometabolic disease [252, 283].  In contrast to most other adipokines circulating 
levels of adiponectin are reduced in obesity, type 2 diabetes and associated conditions [252, 283].  
In addition, adiponectin knockout mice or humans with polymorphisms that decrease adiponectin 
production typically develop cardiometabolic dysfunction and or type 2 diabetes [252, 283].  For 
these reasons, therapeutic strategies to increase the circulating levels of adiponectin are considered 
attractive. 
Heme oxygenase-1 (HO-1) is a stress-inducible protein that catalyses the oxidative degradation of 
heme to produce carbon monoxide (CO), iron and biliverdin/bilirubin [261, 284].  These catalytic 
products modulate diverse features of cellular function and homeostasis in response to oxidative, 
inflammatory and metabolic stress [207, 261, 284].  In accordance with this, induction of HO-1 is 
typically promoted as an attractive therapeutic approach to reduce the incidence and severity of a 
variety of human diseases that include obesity and type 2 diabetes [195, 262, 284].  As such, 
strategies to induce HO-1 in humans are under investigation [206, 207, 263]. 
Evidence, primarily from preclinical in vivo studies, supports the notion that induction of HO-1 may 
give rise to beneficial effects via an increase in circulating adiponectin levels leading to the 
proposal of a “HO-1 – adiponectin axis” [217, 225-227, 230, 236, 239, 241, 242, 265, 267, 268, 
285-287].  In the absence of any evidence to support a direct effect of HO-1 on adiponectin 
production from adipocytes we recently performed a study to determine whether acute (24-48 h) 
induction of HO-1, using two commonly used agents - cobalt protoporphyrin (CoPP) or hemin, 
increased adiponectin production from mature human adipocytes.  Surprisingly, despite robust 
induction of HO-1 we saw no evidence of enhanced adiponectin production (expression or secretion) 
from healthy adipocytes or adipocytes where adiponectin production was reduced by co-treatment 
with TNFα [288].  While these findings argued against the existence of a direct HO-1 – 
adiponectin axis they did not address the potential effects of chronic induction of HO-1 on 
adiponectin production.  Indeed, reports suggested that chronic induction of HO-1 throughout the 
process of differentiation promoted increased adiponectin secretion, albeit in the face of reduced 
differentiation [238, 242].  Although this seemed paradoxical we previously reported that 
adiponectin secretion was highest in immature adipocytes differentiated in vitro [278], hence we 
reasoned that chronic HO-1 induction may arrest differentiation at a stage where adiponectin 
production was higher than in the mature adipocyte.  Thus, in the current study we performed a 
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comprehensive series of investigations to determine whether chronic treatment with CoPP or hemin, 
across appropriate dose-response curves, could increase adiponectin production from human 
preadipocytes differentiated in vitro.  We found that chronic treatment with both agents promoted 
dose-dependent inhibition of differentiation and also reduced the expression and secretion of 
adiponectin. 
In an attempt to define the underlying processes we explored potential mechanisms.  CoPP and 
hemin induce HO-1 expression, at least in part, by increasing the stability and activity of the 
transcription factor Nuclear factor erythroid-derived 2-like 2 (NRF2) [275].  NRF2 is a critical 
regulator of the antioxidant defence pathway that appears to play a complex role in the regulation of 
adipogenesis and adipose tissue biology [289].  The expression of two NRF2 target genes, NQO1 
and GCLM, confirmed dose-dependent activation of NRF2 upon CoPP or hemin treatment.  
Combined with investigations using a HO-1 inhibitor or HO-1 siRNA we provide evidence which 
demonstrates that the inhibitory effects of CoPP or hemin are independent of HO-1 but appear to be 
linked to some other downstream effector(s), possibly one or more NRF2 target genes. 
 
 
3.4 Methods 
 
3.4.1 Reagents and antibodies 
General reagents were obtained from Sigma-Aldrich (Victoria, Australia), unless otherwise stated.  
Cell culture reagents were obtained from Invitrogen (Victoria, Australia). 
 
3.4.2 Isolation, culture, differentiation and treatment of primary human 
preadipocytes 
Primary human preadipocytes (phPAs) were isolated from subcutaneous adipose tissue from 4 
subjects (all female, age 30.5 ± 6.2 years, BMI 23.45 ± 0.46, metabolically healthy - no insulin 
resistance, diabetes or cardiovascular disease) and cultured independently as described previously 
[270]. The procedure was approved by the Research Ethics Committees of the University of 
Queensland, the Princess Alexandra Hospital, and Mater Adults Hospital. All patients had given 
their written informed consent.  Cells were differentiated in the continued presence of vehicle 
Mengliu Yang 
62 
 
(DMSO) or CoPP (0.1 - 0.25 μM) for 21 days.  Cells and conditioned media were harvested on 
day 21. 
 
3.4.3 Cell culture, differentiation, and treatment of SGBS PAs 
SGBS PAs [269] were routinely maintained and differentiated as described [270]. In brief, cells 
were cultured in DMEM/F12 containing 10%FCS, penicillin, 33 M biotin, and 17 M pantothenic 
acid until confluent. To differentiate, the cells were then cultured in serum-free DMEM/F12 
supplemented with penicillin, 33M biotin, 17M pantothenic acid, 0.01 mg/mL transferring, 0.1 
M corisol, 200 pM triiodotyronine, 20 nM human insulin, 0.25 M dexamethasone (DEX), 500 
M methylisobutylxanthine (MIX), 2 M rosiglitazone, 90 g/mL heparin and 1 ng/mL FGF-1 for 3 
days. On day 3, medium was changed to differentiation medium without rosiglitazone and from day 
7 to the completion of the differentiation, cells were cultured in the differentiation medium without 
rosiglitazone, MIX and DEX. SGBS PAs were differentiated in the presence of vehicle (DMSO) or 
CoPP (0.1 - 0.25 μM) or Hemin (0.5 - 5 μM) for 14 days.  For experiments performed in the 
presence of serum, cells were differentiated and maintained in media containing 10% foetal bovine 
serum (FBS) in the continued presence of vehicle (DMSO) or CoPP (1 - 5 μM) for 14 days [288].  
For experiments involving co-treatment with the HO-1 inhibitor SnMP (Frontier scientific services, 
New Jersey, USA), cells were differentiated in the continued presence of vehicle (DMSO), CoPP 
(0.25 μM) or Hemin (3 μM), with or without SnMP (5 μM) for 14 days. 
For experiments involving siRNA mediated HO-1 knockdown SGBS-PAs were transfected at 80% 
confluence with scrambled (Scr) control siRNA (AATTCTCCGAACGTGTCACGT) or HO-1 
siRNA (CAGGCAGAGGGTGATAGAAGA) at 50 nM (Qiagen, Victoria, Australia) using 
NanoJuice (Novagen, Darmstadt, Germany) according to the manufacturer’s instructions.  72 h 
post-transfection cells were induced to differentiate in the continued presence of vehicle (DMSO), 
CoPP (0.25 μM) or Hemin (3 μM) for 14 days. For all experiments cells and conditioned media 
were harvested on day 14. 
 
3.4.4 Measurement of gene expression by qRT-PCR 
Gene expression was measured by qRT-PCR and standardized against the expression of cyclophilin 
as previously described [270]. Briefly, total RNA extraction was performed using Trizol or RNA 
Mini Kit (Ambion Life Technologies, Victoria, Australia) according to the manufacturer's 
instructions. Complementary DNA (cDNA) was synthesized from 1 µg total RNA  using a cDNA 
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synthesis kit (Bioline, NSW, Australia) and RT-PCR was performed using the SYBR Hi-ROX kit 
(Bioline) on a 7900HT Fast Real-time PCR system (Ambion Life Technologies).  Primer 
sequences were as follows (all human, listed as Forward / Reverse):  Cyclophilin - 
CGCGTCTCCTTTGAGCTGTT / TCTCCAGTGCTCAGAGCACG;   HO-1 - 
CCAGGCAGAGAATGCTGAGTTC / AAGACTGGGCTCTCCTTGTTGC;   ADIPOQ - 
AGAAAGGAGATCCAGGTCTTATTGGT / AACGTAAGTCTCCAATCCCACACT;  NQO1 - 
CCTGCCATTCTGAAAGGCTGGT / GTGGTGATGGAAAGCACTGCCT;  GCLM - 
TCTTGCCTCCTGCTGTGTGATG / (R) TTGGAAACTTGCTTCAGAAAGCAG;  PPARγ - 
GAAACTTCAAGAGTACCAAAGTGCAA / AGGCTTATTGTAGAGCTGAGTCTTCTC;  
ADIPOR1 - CATCGTCTGTGTCCTGGGCATT / CTTGACAAAGCCCTCAGCGATAG;  
ADIPOR2 - GCCTCTACATCACAGGAGCTGC / CCTGGAGGTTTGAGACACCATG;  GLUT4 
- CTCTCTGGCATCAATGCTGT / ACCGAGACCAAGGTGAAGAC; GLUT1 - 
TTGCAGGCTTCTCCAACTGGAC / CAGAACCAGGAGCACAGTGAAG; IL-6 - 
AGACAGCCACTCACCTCTTCAG / TTCTGCCAGTGCCTCTTTGCTG 
 
3.4.5 Determination of HO-1 and adiponectin protein  
Cellular HO-1 was quantitated in whole cell lysates (in 0.05-0.25 μg protein) using an HO-1 ELISA 
(Life Sciences, Florida, USA). Secreted total adiponectin present in conditioned media was 
quantitated using a total adiponectin ELISA kit (R&D system, Minnesota, USA). 
 
3.4.6 Measurement of 2-Deoxyglucose uptake 
Glucose uptake was measured in SGBS cells on day 14 of differentiation as described [270]. In 
brief, cells were washed three times and incubated in warm KRH (136 mM NaCl, 4.7 mM KCl,10 
mM HEPES, 1.25 mM MgSO4,1.25 mM CaCl2, pH 7.4) buffer at 37°C for 2 h. The cells were then 
stimulated with 100 nM insulin for 20 min at 37°C. The cells for negative control (background) 
were treated with cytochalasin B for 1 min prior to [3H]2-deoxyglucose (Amersham, Little Chalfont, 
UK) administration. After that, a mixture of 50 μM 2-deoxyglucose containing 1 μCi/mL 
[3H]deoxyglucose was added for 20 min at 37°C. The reaction was stopped by removal of media 
and addition of ice-cold PBS. The cells were harvested in 1% Triton X-100 (in PBS) and 
solubilized in Optiphase “supermix” liquid scintillant (Perkin Elmer, Wellesley, MA) and counted 
in a Microbeta Jet 1450 LSC beta counter (Perkin Elmer). 
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3.4.7 Statistical analysis 
Data are presented as means ± SEM. One-way ANOVA was used to compare between treatment 
groups with Tukey’s post hoc test. Two-way ANOVA with Bonferroni’s post hoc test was used to 
compare between gene expression levels at the same CoPP concentration.  Paired student t-test 
was used to compare the significant difference between SnMP or siRNA treated with control (Figs 
2.5-7).  Differences were considered statistically significant at p<0.05.  Statistical analyses were 
performed in GraphPad Prism 5.0. 
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3.5 Results 
 
3.5.1 Chronic treatment of primary phPAs with CoPP inhibits adipogenesis and 
adiponectin production 
We first investigated the effects of chronic HO-1 induction on differentiation and adiponectin 
production from phPAs using the widely used inducer of HO-1, CoPP.  Cells were differentiated 
for 21 days in the presence of increasing concentrations of CoPP ranging from 0.1 – 0.5 µM 
(determined in preliminary investigations – data not shown).  The effects of CoPP were apparent 
morphologically, with increasing CoPP concentrations reducing lipid accumulation (Fig 3.1a).  
Analysis of HO-1 expression confirmed marked induction in response to CoPP, with HO-1 levels 
increased 15-30 fold (Fig 3.1b).  Interestingly, the induction of two other NRF2-target genes [289], 
NQO1 and GCLM, was more modest (Fig 3.1b).  We measured mRNA expression of a number of 
adipogenic/adipocyte markers to further define the effect of CoPP on differentiation.  Consistent 
with the reduction in lipid accumulation, the expression of early (PPARγ), intermediate (ADIPOR2), 
and late (GLUT4) markers of adipogenesis were all decreased in a dose-dependent manner, with the 
latter showing the greatest sensitivity to CoPP (Fig 3.1c).  The expression of ADIPOR1, which is 
unchanged during differentiation (data not shown), was unaffected by CoPP treatment (Fig 3.1c) 
demonstrating the specificity of the effect on the differentiation process.  Consistent with the 
effects of CoPP on adipogenesis, key indices of adiponectin production, namely expression and 
secretion, were also decreased by CoPP in a dose-dependent manner (Fig 3.1d).  Interestingly, 
adiponectin secretion exhibited greater sensitivity to CoPP than adiponectin expression (Fig 3.1d).  
To investigate the effect of CoPP on cellular stress and inflammation we evaluated the expression 
levels of GLUT1 and IL-6 because upregulation of GLUT1 occurs in response to cellular stress [290] 
and IL-6 expression has been reported to be decreased upon chronic treatment with CoPP [291].  
At the highest concentration of CoPP, expression of both GLUT1 and IL-6 was significantly 
increased (Fig 3.1e).  Collectively, these findings indicate that treatment of phPAs with CoPP 
results in dose-dependent inhibition of differentiation and adiponectin production and, at high 
concentrations, induces cellular stress. 
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Fig 3.1 - Chronic treatment of phPAs with CoPP decreases adipogenesis and adiponectin 
production. phPAs were differentiated for 21 days in the presence of increasing concentrations of 
CoPP (0.1-0.5 μM).  (a) Images showing cell morphology on day 21.  (b) HO-1, NQO1 and 
GCLM expression determined by qRT-PCR (n=4; *p<0.05 vs control; one-way ANOVA with 
Tukey’s post hoc test: #p<0.05 vs HO-1 expression at the same CoPP concentration; two-way 
ANOVA with Bonferroni’s post hoc test).  (c) Adipocyte markers (PPAR, ADIPOR2, GLUT4) 
and ADIPOR1 expression determined by qRT-PCR (n=4; *p<0.05 vs control; one-way ANOVA 
with Tukey’s post hoc test).  (d) Adiponectin expression and secretion determined by qRT-PCR 
and ELISA (n=4; *p<0.05 vs control; one-way ANOVA with Tukey’s post hoc test, #p<0.05 vs 
adiponectin expression levels at the same CoPP concentration; two-way ANOVA with Bonferroni’s 
post hoc test).  (e) GLUT1 and IL-6 expression determined by qRT-PCR (n=4; *p<0.05 vs control; 
one way-ANOVA with Tukey’s post hoc test; #p<0.05 vs GLUT1 expression levels at the same 
CoPP concentration after two-way ANOVA with Bonferroni’s post hoc test). 
 
3.5.2 Chronic treatment of Simpson Golabi Behmel Syndrome preadipocytes (SGBS 
PAs) with CoPP inhibits adipogenesis and adiponectin production 
To extend our observations from phPAs, we performed similar studies in the widely used human 
SGBS-PA cell strain [270, 278, 292, 293].  Chronic CoPP treatment throughout differentiation 
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reduced lipid accumulation in a dose-dependent manner (Fig 3.2a).  As expected, CoPP induced 
the expression of HO-1 as well as NQO1 and GCLM (Fig 3.2b).  Consistent with our observations 
in the phPAs induction of HO-1 was greater than that observed for NQO1 and GCLM and, 
interestingly, only induction of the latter two appeared dose-dependent under these experimental 
conditions.  In keeping with the dose-dependent effects of CoPP on lipid accumulation and NQO1 
and GCLM expression, and in contrast to the effects on HO-1 induction, we also observed 
dose-dependent inhibitory effects of CoPP on expression of markers of adipogenesis and 
adiponectin production (Fig 3.2c & d) and increased expression of markers of cellular stress and 
inflammation GLUT1 and IL-6 (Fig 3.2e).  The latter probably contributes to the relatively modest 
induction of HO-1 (≈10-fold) in cells treated at the highest concentration of CoPP (Fig 3.2b).  
Next, we measured basal and insulin-stimulated glucose uptake to explore the functional impact of 
these effects, particularly the changes in GLUT1 and GLUT4 which encode the glucose transporters 
responsible for basal and insulin-stimulated glucose transport in these cells.  Consistent with the 
changes in gene expression we observed a dose-dependent increase in basal glucose uptake and a 
concomitant reduction in the ability of insulin to stimulate glucose uptake (Fig 3.2f).  These 
observations confirm and extend our findings from the phPAs. 
 
Fig 3.2 - Chronic treatment of SGBS PAs with CoPP decreases adipogenesis and adiponectin 
production. SGBS PAs were differentiated for 14 days in the presence of increasing concentrations 
of CoPP (0.1-0.5 μM).  (a) Images showing cell morphology on day 14.  (b) HO-1, NQO1 and 
GCLM expression determined by qRT-PCR (n=4; *p<0.05 vs control; one-way ANOVA with 
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Tukey’s post hoc test: #p<0.05 vs HO-1 expression at the same CoPP concentration; two-way 
ANOVA with Bonferroni’s post hoc test).  (c) Adipocyte markers (PPAR, ADIPOR2, GLUT4) 
and ADIPOR1 expression determined by qRT-PCR (n=4; *p<0.05 vs control; one-way ANOVA 
with Tukey’s post hoc test).  (d) Adiponectin expression and secretion determined by qRT-PCR 
and ELISA (n=4; *p<0.05 vs control; one-way ANOVA with Tukey’s post hoc test).  (e) GLUT1 
and IL-6 expression determined by qRT-PCR (n=4; *p<0.05 vs control; one way-ANOVA with 
Tukey’s post hoc test; #p<0.05 vs GLUT1 expression levels at the same CoPP concentration after 
two-way ANOVA with Bonferroni’s post hoc test). (f) basal and insulin-stimulated glucose uptake 
(n=4; *p<0.05 vs non-insulin stimulated glucose uptake after two-way ANOVA with Bonferroni’s 
post hoc test). 
 
3.5.3 The addition of exogenous HO-1 substrate does not modulate the negative 
effects on adipogenesis or adiponectin production 
In accordance with our standard experimental approaches both the phPAs and SGBS PAs were 
differentiated in the absence of serum [270, 278, 293] raising the possibility that the inhibitory 
effects of CoPP may reflect, at least in part, a shortage of substrate for HO-1 as it has been 
suggested that substrate may be limiting under such conditions [213].  To investigate this we 
employed two complementary approaches.  First, we examined the effects of hemin, which serves 
as both HO-1 inducer and substrate [213, 275], on differentiation of SGBS PAs.  Preliminary 
investigations identified a dose-response regime where chronic hemin treatment reduced lipid 
accumulation (Fig 3.3a), akin to that observed for CoPP (see Fig 3.2a).  Analysis of gene 
expression profiles revealed that hemin dose-dependently induced HO-1 and, again, this induction 
was greater than that observed for NQO1 and GCLM (Fig 3.3b), although the magnitude of these 
effects was 3-4 fold less than those observed for CoPP.  Chronic hemin treatment also 
dose-dependently reduced expression of adipogenic markers (Fig 3.3c) and adiponectin production 
(Fig 3.3d), with secretion again showing greater sensitivity than expression, and significantly 
increased expression of IL-6 (Fig 3.3e).  
 
Our second approach was to characterize the effects of CoPP on SGBS PAs in the presence of 10% 
foetal bovine serum, which contains substrate for HO-1 [213].  The inclusion of serum reduced the 
apparent sensitivity to CoPP, which most likely reflects the binding and sequestering of CoPP to 
serum factors, such that experiments were performed using CoPP at 1-5 µM.  There was a clear 
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decrease in lipid accumulation in cells treated with 2.5 and 5 µM CoPP but not in cells treated with 
1 µM CoPP (Fig 3.4a).  Induction of HO-1 was ≈15-fold in cells treated with 1 µM CoPP 
peaking at 30-35-fold in cells treated at the higher concentrations (Fig 3.4b).  Induction of NQO1 
and GCLM was dose-dependent (ranging from 2-8-fold) but, as before, was less than that observed 
for HO-1 (Fig 3.4b).  Interestingly, significant reductions in expression of adipogenic markers 
were only observed in cells treated with 5 µM CoPP, with no effects observed in cells treated at 1 
µM and only non-significant trends (10-20%) in cells treated with 2.5 µM (Fig 3.4c).  In contrast, 
adiponectin expression and secretion were significantly reduced in cells treated with 2.5 µM CoPP, 
by around 50 and 70% respectively (Fig 3.4d).  Interestingly, GLUT1 and IL-6 exhibited 
counter-regulation with GLUT1 significantly increased and IL-6 significantly decreased in response 
to treatment with 5 µM CoPP (Fig 3.4e). 
Taken together, the above results demonstrate that chronic treatment of human preadipocytes with 
either CoPP or hemin interferes with both differentiation and adiponectin production.  However, 
inconsistencies between the dose-response of HO-1 induction and inhibition of adipogenesis and 
adiponectin production were apparent and prompted us to investigate the putative role of HO-1 
activity and HO-1 protein in these effects in more detail. 
 
Fig 3.3 - Chronic treatment of SGBS PAs with hemin decreases adipogenesis and adiponectin 
production. SGBS PAs were differentiated for 14 days in the presence of increasing concentrations 
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of hemin (0.5-5 μM).  (a) Images showing cell morphology on day 14.  (b) HO-1, NQO1 and 
GCLM expression determined by qRT-PCR (n=4; *p<0.05 vs control; one-way ANOVA with 
Tukey’s post hoc test: #p<0.05 vs HO-1 expression at the same CoPP concentration; two-way 
ANOVA with Bonferroni’s post hoc test).  (c) Adipocyte markers (PPAR, ADIPOR2, GLUT4) 
and ADIPOR1 expression determined by qRT-PCR (n=4; *p<0.05 vs control; one-way ANOVA 
with Tukey’s post hoc test).  (d) Adiponectin expression and secretion determined by qRT-PCR 
and ELISA (n=4; *p<0.05 vs control; one-way ANOVA with Tukey’s post hoc test).  (e) GLUT1 
and IL-6 expression determined by qRT-PCR (n=4; *p<0.05 vs control; one way-ANOVA with 
Tukey’s post hoc test; #p<0.05 vs GLUT1 expression levels at the same CoPP concentration after 
two-way ANOVA with Bonferroni’s post hoc test). 
 
 
 
Fig 3.4 - Chronic treatment with CoPP decreases adipogenesis and adiponectin production 
from SGBS PAs in serum. SGBS PAs were differentiated for 14 days in serum containing medium 
in the presence of increasing concentrations of CoPP (1-5 μM).  (a) Images showing cell 
morphology on day 14.  (b) HO-1, NQO1 and GCLM expression determined by qRT-PCR (n=4; 
*p<0.05 vs control; one-way ANOVA with Tukey’s post hoc test: #p<0.05 vs HO-1 expression at 
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the same CoPP concentration; two-way ANOVA with Bonferroni’s post hoc test).  (c) Adipocyte 
markers (PPAR, ADIPOR2, GLUT4) and ADIPOR1 expression determined by qRT-PCR (n=4; 
*p<0.05 vs control; one-way ANOVA with Tukey’s post hoc test).  (d) Adiponectin expression 
and secretion determined by qRT-PCR (n=4) and ELISA (n=3; *p<0.05 vs control; one-way 
ANOVA with Tukey’s post hoc test).  (e) GLUT1 and IL-6 expression determined by qRT-PCR 
(n=4; *p<0.05 vs control; one way-ANOVA with Tukey’s post hoc test). 
 
3.5.4 Co-treatment with a HO-1 inhibitor (SnMP) does not prevent the inhibitory 
effects of CoPP or hemin on adipogenesis or adiponectin production 
To investigate whether the inhibitory effects of CoPP and hemin were associated with increased 
HO-1 activity we performed a series of experiments in the presence or absence of SnMP, a widely 
used inhibitor of HO-1 activity [243, 294].  Treatment of cells with SnMP (5 µM) had no obvious 
effect on lipid accumulation in control cells or in cells treated with CoPP (0.25 µM) or hemin (3 
µM) (Fig 3.5a).  Treatment with SnMP tended to increase the levels of HO-1 mRNA and protein 
under all conditions, reaching significance for HO-1 in control and hemin treated cells (Fig 3.5b & 
c).  This effect is consistent with other reports [214, 243] and demonstrates the efficacy of the 
SnMP treatment.  Similar results were observed for NQO1 and GCLM (Fig 3.5d & e).  Consistent 
with these observations, whilst we typically observed no significant impact of SnMP treatment on 
the expression of adipogenic markers across the various conditions, co-treatment with SnMP 
modestly, but consistently exacerbated the effects of CoPP or hemin (reducing PPAR, ADIPOR2 
and GLUT4 expression by a further 20-30%) reaching significance for co-treatment with CoPP on 
ADIPOR2 expression (Fig 3.5f-h).  Similar effects were apparent when the effects of SnMP on 
adiponectin production were determined (Fig 3.5i & j), most notably for adiponectin secretion 
which was significantly reduced upon co-treatment with SnMP in the presence of either CoPP or 
hemin (Fig 3.5j).  Similarly, co-treatment with SnMP exacerbated the effects of CoPP or hemin on 
IL-6 expression (Fig 3.5k).  Collectively, these observations do not support a model whereby the 
inhibitory effects of CoPP or hemin on adipogenesis and adiponectin production are mediated by 
HO-1 activity. 
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Fig 3.5 – Co-treatment with the HO-1 inhibitor SnMP does not prevent the effects of CoPP or 
hemin.  SGBS PAs were differentiated for 14 days in the presence of CoPP (0.25 µM) or hemin (3 
μM) in the presence of SnMP (5 µM) where indicated.  (a) Images showing cell morphology on 
day 14.  (b) HO-1 expression and (c) HO-1 protein determined by qRT-PCR and ELISA.  (d) 
NQO1 and (e) GCLM expression determined by qRT-PCR.  Expression of adipocyte markers (f) 
PPARγ, (g) ADIPOR2 and (h) GLUT4 determined by qRT-PCR. Adiponectin (i) expression and (j) 
secretion determined by qRT-PCR and ELISA. (k) IL-6 expression determined by qRT-PR  (for 
all graphs n=3; *p<0.05; Paired student t-test was used to determine whether treatment with SnMP 
had any significant effect).  
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3.5.5 HO-1 knockdown does not prevent the inhibitory effects of CoPP or hemin on 
adipogenesis or adiponectin production 
Having established that increased HO-1 activity is unlikely to mediate the inhibitory effects of 
CoPP and hemin on adipogenesis and adiponectin production we next performed a series of 
experiments to investigate the effects of siRNA mediated HO-1 knockdown.  Treatment with 
HO-1 specific siRNA had no obvious effect on lipid accumulation in control or CoPP treated cells 
(Fig 3.6a) despite reducing HO-1 mRNA and protein levels by 50-60% (Fig 3.6b & c).  Expression 
of NQO1 was significantly increased in response to HO-1 knockdown in control and CoPP cells and 
a similar pattern was observed for GCLM although this failed to reach statistical significance (Fig 
3.6d & e).  Collectively, these results demonstrated that the HO-1 knockdown was reasonably 
efficient (>50%) and was sufficient to alter expression of NRF2 target genes.  In contrast, HO-1 
knockdown did not reverse the effects of CoPP on the expression of adipogenic markers, 
adiponectin production or IL-6 (Fig 3.6f-k).   
Similar experiments were performed in cells treated with hemin and these gave comparable results.  
HO-1 knockdown had no obvious effect on lipid accumulation in control or hemin treated cells (Fig 
3.7a), despite reducing both basal and hemin-induced HO-1 mRNA and protein by 50-60% (Fig 
3.7b & c).  Expression of NQO1 and GCLM was generally increased upon HO-1 knockdown (Fig 
3.7d & e) whilst the effects of hemin on expression of adipogenic markers, adiponectin production 
and IL-6 expression were unaffected or exacerbated (Fig 3.7f-k). 
These results indicate that chronic treatment of human preadipocytes with CoPP or hemin interferes 
with the process of adipogenesis and subsequent production of adiponectin by a mechanism that is 
not coupled to either HO-1 activity or protein. 
Mengliu Yang 
74 
 
 
Fig 3.6 – HO-1 knockdown does not prevent the effects of CoPP.  SGBS PAs were transfected 
with scrambled (vehicle) or HO-1 siRNA for 72 h  then differentiated for 14 days in the presence 
of CoPP (0.25 µM).  (a) Images showing cell morphology on day 14.  (b) HO-1 expression and 
(c) HO-1 protein determined by qRT-PCR and ELISA.  (d) NQO1 and (e) GCLM expression 
determined by qRT-PCR.  Expression of adipocyte markers (f) PPARγ, (g) ADIPOR2 and (h) 
GLUT4 determined by qRT-PCR. Adiponectin (i) expression and (j) secretion determined by 
qRT-PCR and ELISA. (k) IL-6 expression determined by qRT-PR  (for all graphs n=3; *p<0.05; 
Paired student t-test was used to determine whether HO-1 knockdown had any significant effect). 
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Fig 3.7 – HO-1 knockdown does not prevent the effects of hemin.  SGBS PAs were transfected 
with scrambled (vehicle) or HO-1 siRNA for 72 h  then differentiated for 14 days in the presence 
of hemin (3 µM).  (a) Images showing cell morphology on day 14.  (b) HO-1 expression and (c) 
HO-1 protein determined by qRT-PCR and ELISA.  (d) NQO1 and (e) GCLM expression 
determined by qRT-PCR.  Expression of adipocyte markers (f) PPARγ, (g) ADIPOR2 and (h) 
GLUT4 determined by qRT-PCR. Adiponectin (i) expression and (j) secretion determined by 
qRT-PCR and ELISA. (k) IL-6 expression determined by qRT-PR  (for all graphs n=3; *p<0.05; 
Paired student t-test was used to determine whether HO-1 knockdown had any significant effect). 
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3.6 Discussion 
The increase in prevalence and severity of obesity related cardiometabolic diseases continues to 
drive efforts to identify novel and efficacious therapeutic approaches [295].  One such strategy is 
to identify pharmacological approaches to increase adiponectin production [283].  In the current 
report we have investigated the hypothesis that chronic induction of HO-1 will modulate 
differentiation of human preadipocytes in a manner that results in increased adiponectin production 
[217, 230, 239].   We demonstrate that under all conditions tested, chronic induction of HO-1 with 
either CoPP or hemin resulted in dose-dependent inhibition of differentiation concomitant with 
induction of NRF2 target genes.  However, under no conditions was adiponectin production 
enhanced.  Further investigations involving co-treatment with an inhibitor of HO-1 activity or 
siRNA-mediated HO-1 knockdown, combined with inconsistencies across dose responses, indicate 
that these effects are HO-1-independent.   We propose that they are most-likely mediated by an 
alternate pathway, possibly involving one or more NRF2 target genes [296].  Collectively, these 
findings suggest that any beneficial effects following chronic treatment with CoPP or hemin in vivo 
are unlikely to be mediated by a direct positive effect of HO-1 induction on adipogenesis of 
preadipocytes.  These findings are consistent with independent studies that found no beneficial 
effect when genetic approaches were used to manipulate HO-1 in adipocytes [204, 281]. 
An increasing number of studies have put forward the existence of a ‘HO-1 – adiponectin axis’.  
Typically, investigations which have led to this proposal have involved chronic induction of HO-1 
using pleiotropic agents such as CoPP, hemin (or derivatives) or epoxyeicosatrienoic acid 
(EET)-agonists in vivo and or in vitro [217, 225-227, 230, 236, 239, 241, 242, 265, 267, 268, 
285-287].  Whilst a primary effect of these agents is to induce HO-1 expression and activity it is 
not the sole effect.  Indeed, these agents induce HO-1 expression, at least in part, by modulation of 
broad acting transcriptional repressors and transcription factors.  More specifically, they involve 
post-translational downregulation of BACH1 and upregulation of NRF2 [275, 291, 297, 298].  The 
latter is recognised as a key regulator of cellular defence against oxidative stress that is also strongly 
implicated in modulation of adipogenesis and adipose tissue remodelling [289, 299, 300].  Thus, 
when using such pleiotropic agents additional experimental strategies are required to ascribe a 
defined role to the induction of HO-1 in such processes. 
In the current study we first performed a comprehensive series of carefully controlled in vitro 
investigations in phPAs and SGBS PAs which demonstrated that chronic treatment with CoPP or 
hemin resulted in dose-dependent inhibition of differentiation (as determined morphologically, 
genetically and functionally) and adiponectin production (expression and secretion) as well as 
Mengliu Yang 
77 
 
induction of NRF2 target genes (see Figs 3.1-3.4).  Under no conditions did we observe any 
evidence of an increase in adiponectin production.  This finding is consistent with the observed 
reduction in PPAR expression, given the pivotal role of this transcription factor in adiponectin 
production [301], combined with the potential for downregulation of PPAR activity by CDK5 
[302], which is upregulated upon induction of HO-1 [303].  Nevertheless, these in vitro 
observations contrast with numerous reports based largely on studies from one group involving 
bone marrow derived mesenchymal stem cells (BMSCs) differentiated in vitro in the continued 
presence of CoPP [238, 242, 243, 294] or EET-agonists [230, 291, 294].  Whilst the reasons for 
these differences are unclear differences in experimental approaches may contribute, although such 
details are typically difficult to determine in the above studies. It also remains possible that 
adiponectin production from BMSCs may be regulated differently in response to these treatments 
than in preadipocytes derived from subcutaneous white adipose tissue, as were used throughout the 
current study.  Indeed, recent findings showing caloric restriction increased adiponectin production 
from bone marrow adipose tissue but not white adipose tissue support such a scenario [304].  
Direct comparisons between the different cell-types, under tightly controlled experimental 
conditions, are warranted to investigate this possibility. 
Interestingly, there was no suggestion of dose-dependent induction of HO-1 by CoPP when the 
SGBS PAs were differentiated in the absence of serum (see Fig 3.2), conditions where substrate is 
likely to be limiting [213].  This apparent disconnect, between the dose response of HO-1 
expression and all other parameters, was the first evidence that made us question the role of HO-1 
per se.  We employed two complementary approaches to address this, using SnMP to inhibit HO-1 
activity directly or HO-1 siRNA to reduce HO-1 protein.  These experiments were performed in 
cells treated with intermediate concentrations of CoPP or hemin, such that a decrease in the potency 
of either agent would be apparent.  Perhaps surprisingly, there was no reduction of the effects of 
CoPP or hemin in cells co-treated with SnMP or HO-1 siRNA.  Indeed, we observed a fairly 
consistent pattern across all readouts, some of which were significant, that indicated co-treatment 
with SnMP or HO-1 siRNA enhanced or exacerbated the effects of CoPP or hemin potency.  
Consistent with previous reports [243] treatment with SnMP typically increased HO-1 mRNA and 
protein.  We also observed increased expression of NQO1 and GCLM suggesting that NRF2 
activity was increased by treatment with SnMP or HO-1 siRNA.  One possible explanation for 
these effects is that induction of HO-1 activity represents part of a homeostatic feedback mechanism 
that is unbalanced by treatment with the inhibitor or siRNA, resulting in a rise in NRF2 activity, 
promoting increased transcription of downstream targets including NQO1 and GCLM.  
Nonetheless, these results demonstrate that the increased levels of HO-1 activity or protein are not 
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responsible for the inhibitory effects of CoPP or hemin observed in the human preadipocytes.  
These results contrast with the findings from studies in BMSCs [230, 238, 242, 243, 291, 294].  
Again, the underlying reasons for the observed differences remain obscure. 
Although a large number of reports suggest the beneficial metabolic effects of administration of 
agents such as CoPP or hemin are mediated via increased activity of HO-1, there is an emerging 
body of evidence that argues against this.  For example, the beneficial effects of heme arginate in 
diabetic (db/db) mice were unaffected by co-treatment with a HO-1 inhibitor [282].  Moreover, 
genetic approaches to increase HO-1 in adipocytes have typically failed to improve metabolic 
parameters in the context of diet-induced obesity [204, 281], including the reduction in circulating 
adiponectin levels [281].  The exception to this comes from a study which employed an atypical 
delivery approach involving intracardial injection of a lentiviral construct (aP2-HO-1) to drive 
adipocyte-specific overexpression of HO-1 [209].  Notably, this approach resulted in a significant 
decrease in weight gain with a concomitant reduction in white adipose tissue mass and 
inflammation [209], factors that are sufficient to increase adiponectin levels [252, 283].  It is also 
worth noting that these observations resemble a scenario of caloric restriction, where adiponectin 
production from the bone marrow is increased [304]. 
In summary, in the current report we have investigated the effects of chronic treatment with CoPP 
or hemin on the induction of HO-1 and differentiation of human preadipocytes and adiponectin 
production.  We find that both agents inhibit differentiation and adiponectin production under all 
conditions tested.  Inhibition of HO-1 activity or expression failed to ameliorate these effects as 
well as the induction of other NRF2 target genes NQO1 and GCLM.  These data indicate that 
chronic treatment with CoPP or hemin interfere with differentiation and adiponectin production 
from human preadipocytes in a HO-1-independent manner.  We propose that induction of other 
NRF2 target genes, such as NQO1 [296], may underpin the observed inhibitory effects.  Finally, 
these findings do not support the existence of a direct HO-1 – adiponectin axis. 
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Chapter 4: 
Divergent effects of CoPP, a HO-1 inducer, on 
weight gain, adipose tissue inflammation, 
adiponectin and insulin responsiveness in obese 
mice. 
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4.1 Introduction to this publication 
This Chapter was submitted to Scientific report journal.  In this study, we characterised the effects 
of administration of the widely used HO-1 inducer cobalt protoporphyrin (CoPP) in lean and obese 
mice: 
 Treatment of obese mice with CoPP results in decreased food intake, body weight gain and 
adipocyte size as well as enhanced insulin sensitivity and attenuated liver steatosis. 
 Obese CoPP-treated mice display increased adipose tissue inflammation and reduced 
adiponectin expression but circulating adiponectin levels are increased. 
 Co-administration of a HO-1 inhibitor SnMP in obese mice ameliorated CoPP effects on 
adipose tissue inflammation and blunted CoPP effects on circulating adiponectin, while 
other parameters were unchanged.   
Collectively, these findings indicate that CoPP administration promotes divergent effects on adipose 
tissue, adiponectin and insulin responsiveness. The majority of these effects appear independent of 
HO-1 activity. 
 
 
Yang, M., Ng, C., Keshvari, S., Bulmer, A. C., Barclay, J. L., Whitehead, J. P., Divergent effects of 
CoPP, a HO-1 inducer, on weight gain, adipose tissue inflammation, adiponectin and insulin 
responsiveness in obese mice. Scientific report, submitted 
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4.1 Abstract 
Adiponectin is a beneficial adipocyte-derived hormone with anti-inflammatory and 
insulin-sensitising properties.  Hypoadiponectinemia contributes to obesity-related 
cardiometabolic diseases making strategies to increase adiponectin levels attractive.  Literature 
suggests pharmacological approaches that promote induction of heme-oxygenase-1 (HO-1) increase 
adiponectin levels and reduce inflammation prompting use of the term ‘HO-1 – adiponectin axis’.  
We previously performed in vitro studies using human preadipocytes/adipocytes which argue 
against a direct HO-1 – adiponectin axis.  Here, we characterised the effects of administration of 
the widely used HO-1 inducer cobalt protoporphyrin (CoPP) in lean and obese mice.  CoPP 
administration significantly increased inflammatory gene expression in white adipose tissue 
irrespective of obesity.  In obese mice adiponectin expression was significantly reduced by CoPP 
yet circulating adiponectin levels (total and HMW) were elevated.  Similar trends were observed 
in lean mice.  Additional effects specific to obese mice included reduced food intake, weight gain, 
adipocyte size and liver steatosis and improved insulin responsiveness.  Co-administration of a 
HO-1 inhibitor SnMP in obese mice ameliorated CoPP effects on adipose tissue inflammation and 
blunted CoPP effects on circulating adiponectin.  Other parameters were unchanged.  These 
findings indicate that CoPP administration promotes divergent effects on adipose tissue, adiponectin 
and insulin responsiveness.  The majority of these effects appear independent of HO-1 activity. 
 
Keywords:  Obesity; Therapeutic; Adipokine; Inflammation 
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4.3 Introduction 
The global prevalence of obesity-associated cardiometabolic diseases requires the development of 
novel therapeutic approaches [295, 305].  Adiponectin is an adipocyte-derived hormone that 
displays a range of beneficial cardiometabolic properties including anti-inflammatory and insulin 
sensitizing effects [283, 295].  Paradoxically, circulating adiponectin levels are reduced in obesity 
and this ‘hypoadiponectinemia’ contributes to the aetiology of obesity-associated diseases [283, 
295].  Consistent with this, humans with genetic polymorphisms that reduce adiponectin 
production and mice lacking adiponectin typically develop cardiovascular dysfunction and or type 2 
diabetes [252, 283].  Following on from this, the efficacy of the insulin sensitizing 
thialozidinediones (TZDs), which were used widely for the treatment of type 2 diabetes, correlated 
closely with improvements in adiponectin profiles [260].  Whilst the success of the TZDs provides 
proof-of-principle that strategies that target circulating adiponectin are effective this class of drug 
has largely been withdrawn due to adverse secondary effects, providing momentum for new 
therapeutic approaches in this area [301]. 
An emerging body of evidence suggests that pharmacological induction of the stress-induced 
protein heme oxygenase-1 (HO-1) may promote an increase in circulating adiponectin levels, 
prompting the suggestion of a “HO-1 – adiponectin axis” [217, 225-227, 230, 236, 239, 241, 242, 
265, 267, 268, 285-287].   HO-1 catalyses the oxidative degradation of heme to carbon monoxide 
(CO), iron and biliverdin/bilirubin [261, 284], products that are known to modulate cellular function 
and homeostasis in response to a variety of inflammatory, oxidative and metabolic stresses [207, 
261, 284].  Indeed, strategies to induce HO-1 in humans are under investigation [206, 207, 263] as 
this is generally considered an attractive therapeutic strategy in diseases including obesity and type 
2 diabetes [195, 262, 284].  However, some lines of evidence suggest that HO-1 per se may not be 
involved [282] and may even play a negative role in the aetiology of obesity-associated 
inflammation and cardiometabolic complications [204]. 
In light of these contrasting viewpoints and the absence of any compelling evidence to support a 
direct effect of HO-1 on adiponectin production from adipocytes we recently performed a series of 
in vitro studies to determine the effects of acute or chronic induction of HO-1, using two commonly 
used agents - cobalt protoporphyrin (CoPP) or hemin, on adiponectin production from human 
adipocytes.  In the first study, we showed that induction of HO-1 for up to 48 h did not alter 
adiponectin production (expression or secretion) in either healthy mature adipocytes or in unhealthy 
TNFα-treated adipocytes where adiponectin production was compromised [288].  In the second 
study, we demonstrated that chronic induction of HO-1 throughout the process of adipogenesis 
(where preadipocytes differentiate into mature, insulin responsive adipocytes) compromised 
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adipogenesis and adiponectin production (Yang et al, under review, SREP-16-40083).  Whilst the 
latter finding contrasts with earlier reports [238, 242] mechanistic investigations, using an inhibitor 
of HO-1 activity or HO-1 knockdown, indicated that the inhibitory effects were independent of 
HO-1.  One possibility is that they are mediated by downstream targets of the transcription factor 
Nuclear factor erythroid-derived 2-like 2 (NRF2) [275], a key regulator of the antioxidant defence 
pathway that plays a complex role in the regulation of adipogenesis and adipose tissue [289] that is 
upregulated by CoPP and hemin (Yang et al, under review, SREP-16-40083).   
Collectively, our in vitro studies do not support the existence of a direct HO-1 – adiponectin axis.  
In the current report we have extended these studies by performing a series of investigations to 
characterise the effects of CoPP administration on white adipose tissue (WAT), adiponectin and 
related parameters in lean and obese mice.  We find that CoPP-treatment promotes a range of 
divergent effects on adipose tissue and adiponectin, particularly in obese mice.  Paradoxically, 
obese CoPP-treated mice display increased adipose tissue inflammation and reduced adiponectin 
expression but circulating adiponectin levels are increased.  Co-treatment with a HO-1 inhibitor 
prevents the pro-inflammatory effect of CoPP in adipose tissue but does not restore adiponectin 
expression yet blunts the effect on circulating adiponectin.  These complex and somewhat 
contradictory effects of CoPP are, perhaps surprisingly, consistent with a considered and integrated 
appraisal of the literature.  Moreover, they support the hypothesis that the induction of HO-1 may, 
at least in part, increase circulating adiponectin levels.   
 
4.4 Methods 
 
4.4.1 Reagents and antibodies 
General reagents were obtained from Sigma-Aldrich (Victoria, Australia), unless otherwise stated. 
 
4.4.2 Animals 
All experimental procedures were carried out in accordance with approved protocols by the 
University of Queensland Animal Ethics Unit and were conducted using the Guidelines of the 
National Health and Medical Research Council.  Male C57BL6 mice (Queensland Biological 
Resource, Brisbane, QLD, Australia) were were maintained at 22.0±0.5°C under a 12-h day, 12-h 
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night cycle and fed standard chow diet (SCD) containing 5% of total energy from fat.  At 8 weeks 
of age mice were maintained on SCD or switched to a high fat diet (HFD) (SF04-027, Specialty 
Feeds, 43% energy from fat) for 16 weeks to induce obesity.  CoPP or SnMP were dissolved in 10 
mmol/L Tris base and pH adjusted to pH 7.4-7.8 with 0.1 N HCl.  Vehicle (Tris/HCl solution), 
CoPP (3 mg/kg once per week) and SnMP (20 mg/kg three times a week) were administered by 
intraperitoneal injection for 6 weeks such that all mice in each cohort received either 1 treatment per 
week (cohort 1 - Figs 4.1-4.4) or 3 treatments per week (cohort 2 - Figs 4.5-4.8). Body weight was 
measured every day during the first two weeks after which it was measured once a week. Energy 
intake was calculated by taking into account the energy value of each of the diets (2 kcal energy for 
SCD, and 4.71 kcal energy for HFD) and using this to calculate energy intake based on a simple 
equation X daily food intake (g/day) *Y (kcal/g)=Z kcal/day. 
 
4.4.3 Glucose and Insulin Tolerance Tests (GTT and ITT) 
GTT and ITT were performed in 6 h fasted mice after 5 or 6 weeks of treatment respectively 
(treatment strategy see below). For glucose tolerance, mice were administered glucose (2 g/kg in 
lean mice; 1 g/kg in obese mice) by intraperitoneal injection and blood samples were collected from 
the tail vein at 0, 20, 40, 60, 90 & 120 min for determination of blood glucose and serum insulin.  
For insulin tolerance, mice were administered human insulin (0.75 U/kg) and blood glucose was 
determined at 0, 20, 40, 60, 90 & 120 min. Insulin responsiveness was calculated as the change in 
blood glucose from 0 to 20 min.  
 
 
4.4.4 Hematoxylin and eosin (H&E) staining 
Adipose tissue and liver samples were fixed in 10% buffered formalin phosphate, dehydrated, 
embedded in paraffin, then cut into 5 μm sections for H&E staining.  Sections were rehydrated in 
an alcohol series, stained in hematoxylin for 10-15 min, rinsed in water for 5 min, dipped in acid 
ethanol 10 times. Sections were then rinsed twice in water, stained in eosin for 30 sec, then 
dehydrated in an alcohol series and xylene.  H&E staining was visualised and images captured 
using an inverted epifluorescence microscope (Olympus, USA).  Adipocyte size (diameter) was 
measured using a quantitative image analysis system (Cell Sens, Olympus, USA).  
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4.4.5 Oil Red O staining of liver 
Hepatic lipid accumulation was evaluated in frozen liver sections by Oil Red O staining. Liver 
samples were embedded in OCT compound (PST, Australia) and cut into 3 μm frozen pathological 
sections. Sections were fixed with 10% formalin for 15 min, rinsed with 60% isopropanol for 10 
min, stained with Oil Red O solution for 20 min followed by Harris’s hematoxylin counterstain for 
2 min, and washed in tap water until blue. Sections were subsequently examined and images 
captured using an inverted epifluorescence microscope (Olympus, USA). Images were analysed 
using ImageJ. 
 
4.4.6 RNA extraction and real-time PCR 
Gene expression was measured by quantitative RT-PCR as described [288] using Tata box protein 
(Tbp) as the housekeeper.  Primer sequences were as follows (all mouse, listed as Forward / 
Reverse): Tbp - CTCAGTTACAGGTGGCAGCA / ACCAACAATCACCAACAGCA;   Ho-1 - 
CACTCTGGAGATGACACCTGAG / GTGTTCCTCTGTCAGCATCACC;   Adipoq - 
AGATGGCACTCCTGGAGAGAAG / ACATAAGCGGCTTCTCCAGGCT;  F480 - 
CGTGTTGTTGGTGGCACTGTGA / CCACATCAGTGTTCCAGGAGAC;  Cd68 - 
GGCGGTGGAATACAATGTGTCC / AGCAGGTCAAGGTGAACAGCTG;  Cd11b - 
TACTTCGGGCAGTCTCTGAGTG / ATGGTTGCCTCCAGTCTCAGCA;  Tnfα - 
GGTGCCTATGTCTCAGCCTCTT / GCCATAGAACTGATGAGAGGGAG;  Mcp-1 - 
GCTACAAGAGGATCACCAGCAG / GTCTGGACCCATTCCTTCTTGG;  Ferritin - 
CCTCGAGTTTCAGAACGATCGC / CCTGATTCAGGTTCTTCTCCATG. 
 
4.4.7 Determination of HO-1 protein and circulating total and HMW adiponectin 
protein 
Tissue HO-1 was quantitated using a Mouse HO-1 ELISA (Enzo Life Sciences, NY, USA) 
following the manufacturer’s instructions.  Circulating total adiponectin was quantitated using a 
total adiponectin ELISA Kit (R&D systems – Cat# DY1119, Minneapolis, USA) and HMW 
adiponectin was quantitated using a HMW adiponectin ELISA kit (ALPCO – Cat# 47ADPMS-E01, 
New Hampshire, USA) according to the manufacturer’s instructions. Total and HMW adiponectin 
levels were not comparable across the different manufacturers kits (eg SCD control mice: total 
adiponectin  = 1.2 + 0.2 µg/ml; HMW adiponectin = 3.6 + 1.3 µg/ml) so these data are presented 
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as arbitrary units. 
 
4.4.8 Statistical Analysis 
Data are presented as mean ± SEM. Two-way ANOVA with Bonferroni’s post hoc test was used to 
compare between treatment groups in both lean and obese mice (Fig 4.1-4.4). One-way ANOVA 
was used to compare between vehicle, CoPP and CoPP+SnMP treatment groups with Tukey’s post 
hoc test (Fig 4.5-4.8).  Unpaired student t-test was used to compare differences between vehicle 
and CoPP in adipocyte size and Oil Red O stain.  Differences were considered statistically 
significant at p<0.05.  Statistical analyses were performed in GraphPad Prism 5.0. 
 
 
4.5 Results 
 
4.5.1 CoPP administration transiently decreases food intake and prevents body 
weight gain in obese mice 
Mice were fed either a standard chow diet (SCD) or high fat diet (HFD) for 16 weeks, to induce 
obesity. Body weight of lean (SCD) mice was 31.3 ± 1.11 g (n=28) and that of obese (HFD) mice 
was 43.6 ± 1.99 g (n=30). Mice were maintained on the same diets for a further 6 weeks and 
received weekly administration of CoPP (3 mg/kg once per week) (the dose of CoPP was chosen 
based on dosing used in similar studies [210, 217], to allow direct comparison) or vehicle. Final 
body weight of lean mice was 31.6 ± 1.20 g for control and 30.5 ± 1.34 for CoPP-treated mice 
(n=16 & 12 respectively) whilst that of obese mice was 45.2 ± 2.05 g for control and 43.5 ± 2.49 for 
CoPP-treated mice (n=16 & 14 respectively). 
CoPP treatment had no effect on food intake in lean mice but was associated with a trend towards 
reduced cumulative energy intake in obese mice (Fig 4.1a & b).  More detailed analysis of daily 
food intake in obese mice revealed significant transient reductions in daily energy intake following 
CoPP administration (Fig 4.1c & d).  Consistent with this, transient weekly reduction in energy 
intake, body weight change over the 6 week intervention period was significantly reduced in the 
obese CoPP-treated mice compared with the obese control mice (Fig 4.1c & d).  The 
CoPP-induced reduction in body weight is consistent with other reports [217, 237, 306]. 
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Fig 4.1 - CoPP administration decreases food intake and prevents body weight gain in obese 
mice. Lean (L) and obese (O) mice were maintained on chow (L) or HFD (O) and received weekly 
administration of vehicle (veh) or CoPP (3 mg/Kg) for 6 weeks. (a) Cumulative energy intake over 
the first 14 days of treatment in lean and obese mice (L-veh n=6; L-CoPP n=9; O-veh n=5; O-CoPP 
n=8). (b) Daily energy intake over the first 14 days of treatment in obese mice.  Arrows depict 
Mengliu Yang 
90 
 
administration days. (c) Change in body weight after 6 weeks of treatment with or without CoPP 
(d) The absolute body weight pre and post CoPP treatment (n ≥ 12 for all groups). *p<0.05; 
***p<0.001; two-way ANOVA with a Bonferroni post hoc test. 
 
4.5.2 CoPP administration improves insulin responsiveness and increases 
circulating adiponectin levels in obese mice 
To investigate the potential effects of CoPP on glucose metabolism we performed glucose tolerance 
tests (GTT) and insulin tolerance tests (ITT) after 5 and 6 weeks of treatment respectively.  CoPP 
administration had no effect on glucose tolerance in lean or obese mice (Fig 4.2a & b).  Similarly, 
CoPP had no effect on insulin tolerance in lean mice (Fig 4.2c) however, CoPP significantly 
improved insulin tolerance in obese mice (Fig 4.2d), with insulin promoting a similar response to 
that observed in the lean mice as evidenced by the insulin responsiveness (Fig 4.2e).  We observed 
an inverse correlation between change in body weight and insulin responsiveness in the obese mice 
(Fig 4.2f), which strongly suggests the improvement in insulin responsiveness observed in the obese 
CoPP-treated mice was driven by, at least in part, the reduction in weight gain.   
We next examined the impact of CoPP on circulating adiponectin profiles. Perhaps surprisingly, 
circulating adiponectin levels were not reduced in obese mice in this study. This is consistent with 
other, similar diet-induced obesity studies involving mice in the host lab [307]. Notwithstanding, 
given adipose tissue mass increased threefold in the obese mice it seems reasonable to conclude that 
adiponectin production per unit of adipose tissue was reduced. Circulating levels of both total and 
HMW adiponectin were significantly increased in obese CoPP-treated mice as were circulating 
HMW adiponectin levels in lean CoPP-treated mice (Fig 4.2g & h).   However, unlike the 
correlation between ITT and body weight change, neither total nor HMW adiponectin levels 
correlated with body weight change (r =-0.173, p=0.418 and r =-0.463, p=0.831 respectively).  
Collectively, these findings suggest that in obese mice CoPP administration improves insulin 
responsiveness by a mechanism associated with reduced weight gain whereas it increases 
circulating adiponectin levels by an independent mechanism. 
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Fig 4.2 - CoPP administration improves insulin responsiveness and increases circulating 
adiponectin levels in obese mice. Lean and obese mice were maintained on chow or HFD 
respectively and received weekly administration of vehicle (veh) or CoPP (3 mg/Kg) for 6 weeks.  
Glucose tolerance test (GTT) in (a) lean and (b) obese mice after 5 weeks of treatment (n ≥ 11 for 
all groups).  Insulin tolerance test (ITT) for (c) lean and (d) obese mice after 6 weeks of treatment. 
(e) Quantitation of insulin responsiveness (Δ blood glucose from 0 – 20 min post insulin). (f) 
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Correlation between Δ body weight and insulin responsiveness in obese mice. Circulating levels of 
(g) total and (h) HMW adiponectin after 6 weeks of treatment (n ≥ 11 for all groups; data are 
presented in arbitrary units because total and HMW adiponectin were determined using ELISA kits 
from different manufacturers making absolute values incomparable). *p<0.05; **p<0.01; 
***p<0.001; two-way ANOVA with a Bonferroni post hoc test. Total and HMW adiponectin levels 
were not comparable across the different manufacturers kits (eg SCD control mice: total 
adiponectin  = 1.2 + 0.2 µg/ml; HMW adiponectin = 3.6 + 1.3 µg/ml) so these data are presented 
as arbitrary units. 
 
4.5.3 CoPP administration promotes divergent effects on adipocyte size and 
inflammatory and adiponectin gene expression profiles in white adipose tissue 
Having established that CoPP treatment increased circulating adiponectin levels in obese mice we 
next examined the impact of CoPP administration on adiponectin expression and inflammation in 
WAT.  Histological analysis of epididymal adipose tissue from obese CoPP-treated mice revealed a 
significant reduction in adipocyte size compared to control mice (Fig 4.3a & b).  It seems likely 
that this is also linked to the reduction in weight gain, as highlighted by correlations between 
adipocyte size and body weight gain as well as insulin responsiveness (Fig 4.3c & d).  As expected, 
CoPP administration promoted robust induction of HO-1 gene and protein in epididymal adipose 
tissue from lean and obese mice (Fig 4.3e & f).  Adiponectin gene (Adipoq) expression trended 
towards a reduction in obese verses lean mice (reduced by 40%) but this was not significant, 
probably due to high variability (Fig 4.3g).  Perhaps surprisingly, in light of other publications 
[217, 237, 241, 242, 272, 279, 306] and the effects of CoPP on circulating adiponectin levels, CoPP 
administration reduced Adipoq expression by 30-40%, and this reached significance in the obese 
mice (Fig 4.3g).  We also examined the effects of CoPP administration on markers of immune cell 
infiltration and inflammation, which has been widely reported to play a causative role in the 
aetiology of obesity induced adipose tissue dysfunction and insulin resistance [204, 308-311].  
CoPP administration increased the expression of markers of immune cell infiltration (F480, Cd68 
and Cd11b) and inflammation (Tnfα and Mcp-1) in both lean and obese mice (Fig 4.3h-k).  Similar 
results were observed following analysis of a selection of genes from subcutaneous adipose tissue 
from obese mice, with CoPP administration resulting in robust (15-fold) induction of Ho-1 
expression, reducing Adipoq expression (by 60%), and inducing F480 (3-fold) (Supp Fig 4.9 a-c) 
demonstrating these effects are not specific to epididymal fat but more likely reflect CoPP-induced 
changes throughout WAT. 
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Fig 4.3 - Divergent effects of CoPP on adipocyte size and inflammatory and adiponectin gene 
expression profiles in epididymal adipose tissue. Lean and obese mice were maintained on chow 
or HFD respectively and received weekly administration of vehicle (veh) or CoPP (3 mg/Kg) for 6 
weeks. (a) Histological and (b) quantitative analysis of adipocyte size in epididymal adipose tissue 
in obese mice. Correlations between (c) Δ body weight and adipocyte size and (d) insulin 
responsiveness and adipocyte size in obese mice. HO-1 (e) gene and (f) protein levels in epididymal 
adipose tissue from lean and obese mice. Expression of (g) Adipoq, (h) F480, (i) Cd68, (j) Cd11b, 
(k) Tnfα and (l) Mcp-1 in epididymal adipose tissue from lean and obese mice (n≥8 for all groups). 
*p<0.05; **p<0.01; ***p<0.001; two-way ANOVA with a Bonferroni post hoc test. 
 
4.5.4 CoPP administration promotes divergent effects on hepatic inflammatory gene 
expression and steatosis 
Having established that CoPP increased the inflammatory gene signature in adipose tissue from lean 
and obese mice we next explored the effects of CoPP administration on similar parameters in the 
liver.  CoPP treatment induced Ho-1 expression at the gene and protein level in liver (Fig 4.4a & b) 
although this was relatively modest compared with the levels of induction seen in epididymal 
adipose tissue (typically 5-10 fold less).  Hepatic expression levels of F480 and Cd68, two 
macrophage cell-surface markers, were increased by obesity and by CoPP whilst hepatic expression 
of Cd11b, a neutrophil marker, was increased only by CoPP (Fig 4.4c-e).  In contrast, hepatic 
expression of Tnfα and Mcp-1 was increased only by obesity (Fig 4.4f & g).  Under no conditions 
did CoPP promote any significant reduction in hepatic inflammatory gene expression, in either lean 
or obese mice.  This lack of any overt beneficial effect of CoPP on hepatic gene expression 
profiles is even more surprising when considered in the context of obesity-associated hepatic 
steatosis.  Histological and quantitative analysis of hepatic lipid accumulation in obese mice 
revealed a significant reduction in CoPP-treated mice (Fig 4.4h-j).  Furthermore, the improvement 
in hepatic steatosis correlated with body weight gain, insulin responsiveness and adipocyte size (Fig 
4.4k-m). 
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Fig 4.4 – Divergent effects of CoPP on hepatic inflammatory gene expression and steatosis.  
Lean and obese mice were maintained on chow or HFD respectively and received weekly 
administration of vehicle (veh) or CoPP (3 mg/Kg) for 6 weeks. HO-1 (a) gene and (b) protein 
levels in liver from lean and obese mice. Expression of (c) F480, (d) Cd68, (e) Cd11b, (f) TnfR and 
(g) Mcp-1 in liver from lean and obese mice. (h) H&E and (i) Oil Red O staining showing hepatic 
lipid accumulation and (j) quantitation in obese mice. Correlations between (k) Δ body weight, (l) 
insulin responsiveness and (m) adipocyte size with Oil red O stain. (n ≥ 8 for all groups). 
*p<0.05; **p<0.01; ***p<0.001; two-way ANOVA with a Bonferroni post hoc test. 
 
4.5.5 Co-treatment with SnMP does not prevent the effects of CoPP on food intake 
and body weight in obese mice 
Given the somewhat surprising effects of CoPP on a variety of parameters, particularly the increase 
in adipose tissue inflammation, we repeated the above experiments in a second cohort of obese mice 
with the inclusion of an additional treatment arm which involved co-treatment of CoPP-treated mice 
with the HO-1 inhibitor SnMP.  Co-treatment with SnMP did not prevent the reduction in food 
intake by CoPP (Fig 4.5a).  Consistent with this, co-treatment with SnMP did not prevent the effect 
of CoPP on weight change (Fig 4.5b), with weight gain in both CoPP and CoPP+SnMP mice being 
significantly reduced compared to that in control mice.  These effects suggest that the 
CoPP-induced reduction in food intake and body weight gain are independent of changes in HO-1 
activity. 
 
Fig 4.5 - SnMP co-treatment does not prevent the effects of CoPP on food intake and body 
weight in obese mice. Obese mice were maintained on a HFD and were administered CoPP (3 
mg/Kg; 1 time/week) alone or in combination with SnMP (20 mg/Kg; 3 times/week) or vehicle (veh) 
for 6 weeks such that all mice were treated 3 times/week. (a) Cumulative energy intake over the 
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first 10 days of treatment (n ≥ 7 for all groups). *p<0.05, vehicle vs CoPP; $p<0.05, vehicle vs 
CoPP+SnMP; one-way ANOVA with Tukey’s post hoc test. (b) Change in body weight after 6 
weeks (n ≥ 7 for all groups). **p<0.01; ***p<0.001; one-way ANOVA with Tukey’s post hoc 
test. 
 
4.5.6 Co-treatment with SnMP does not prevent the effects of CoPP on insulin 
responsiveness but blunts the effect on circulating adiponectin levels 
As before, treatment with CoPP did not affect glucose tolerance and co-treatment with SnMP was 
also without effect (Fig 4.6a).  CoPP treatment improved insulin tolerance and this was also 
unaffected by co-treatment with SnMP (Fig 4.6b).  The improvement in insulin responsiveness 
correlated inversely with the change in body weight (Fig 4.6c).  These findings suggest that CoPP 
improves insulin responsiveness by a mechanism that is associated with the change in body weight 
that is independent of HO-1 activity. 
We next examined the impact of co-treatment with SnMP on the effects of CoPP on circulating 
adiponectin profiles.  In contrast to the lack of effect of co-treatment with SnMP on food intake, 
body weight and insulin responsiveness the effects of CoPP on circulating levels of total and HMW 
adiponectin were blunted by co-treatment with SnMP (Fig 4.6c & d).  As before, neither total nor 
HMW adiponectin levels correlated with body weight change (r =-0.285, p=0.188 for both).  These 
findings suggest that CoPP may increase circulating adiponectin levels by a mechanism that is, at 
least in part, dependent on HO-1 activity. 
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Fig 4.6 - SnMP co-treatment does not prevent the CoPP-mediated improvement in insulin 
responsiveness but blunts the effect on circulating adiponectin levels. Obese mice were 
maintained on a HFD and were administered CoPP (3 mg/Kg; 1 time/week) alone or in combination 
with SnMP (20 mg/Kg; 3 times/week) or vehicle (veh) for 6 weeks such that all mice were treated 3 
times/week. (a) Glucose tolerance test (GTT) after 5 weeks and (b) ITT after 6 weeks of treatment 
(n ≥ 7 for all groups). Circulating levels of (c) total and (d) HMW adiponectin after 6 weeks of 
treatment (n ≥ 7 for all groups; data are presented in arbitrary units because total and HMW 
adiponectin were determined using ELISA kits from different manufacturers making absolute 
values incomparable). *p<0.05; **p<0.01; one-way ANOVA with Tukey’s post hoc test. Total and 
HMW adiponectin levels were not comparable across the different manufacturers kits (eg SCD 
control mice: total adiponectin  = 1.2 + 0.2 µg/ml; HMW adiponectin = 3.6 + 1.3 µg/ml) so these 
data are presented as arbitrary units. 
 
4.5.7 Co-treatment with SnMP ameliorates the effects of CoPP on inflammatory 
gene expression profiles in white adipose tissue 
Next we investigated whether co-treatment with SnMP altered CoPP-affected gene expression 
profiles in adipose tissue in obese mice.  Co-treatment with SnMP typically has no effect or even 
exacerbates CoPP induction of HO-1 in vitro thus it was surprising that co-treatment with SnMP in 
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obese mice actually reduced induction of HO-1 at the mRNA and protein level in epididymal 
adipose tissue (Fig 4.7a & b).  This effect of SnMP co-treatment provided the first clear evidence 
of an effect of SnMP co-treatment.  To investigate the effect on HO-1 activity more directly we 
measured Ferritin expression, as this is induced to metabolise the iron released as a by-product of 
the HO-1 catalysed breakdown of heme [213].   CoPP promoted a 3-4 fold increase in Ferritin 
expression and this was reduced by around 60% with the SnMP co-treatment (Fig 4.7c), providing 
further evidence of the efficacy of the SnMP co-treatment.   
SnMP co-treatment promoted amelioration of inflammatory gene induction in all cases, except for 
Cd68 (Fig 4.7d-h).  Whilst the reason for this discrepancy is unclear it is noteworthy that CoPP did 
not increase Cd68 expression (which contrasts to all the other inflammatory genes in this and the 
previous cohort) and that Cd68 levels in the obese mice in this cohort (which were heavier/fatter 
than in the first cohort) were similar to those observed in the obese CoPP-treated mice in the first 
cohort.  Regardless, these data show that SnMP co-treatment prevented the effects of CoPP on 
inflammatory gene expression.  Adipoq expression was dramatically reduced by CoPP in this 
cohort (by 60%) and co-treatment with SnMP appeared to partially prevent this effect (Fig 4.7i).   
In an attempt to better understand the potential molecular pathways responsible for mediating these 
effects we performed correlation analyses of select parameters.  First, we explored the association 
between Ferritin (a surrogate for local HO-1 activity) and Tnfα (a known repressor of adiponectin 
expression) [288].  Ferritin and Tnfα expression showed a positive correlation (Fig 4.7j), strongly 
supporting the hypothesis that increased local HO-1 activity contributed to the increase in Tnfα 
expression.  As expected, subsequent analysis of Tnfα and Adipoq expression revealed an inverse 
correlation (Fig 4.7k).  Hence, it follows that increased HO-1 activity may contribute to the 
reduction in Adipoq expression.  However, correlation analysis of Ferritin and Adipoq expression 
does not directly support this (r=-0.292; p=0.199) and the effects of SnMP co-treatment on 
adiponectin expression were modest (Fig 4.7i).  Taken together these findings suggest that the 
direct effects of local changes in HO-1 activity on Adipoq expression are likely to be modest and 
the changes in Adipoq expression are more likely to reflect the changes in the inflammatory milieu. 
As before, analysis of a selection of genes from subcutaneous adipose tissue produced similar 
results (Supp Fig 4.10).  Interestingly, co-administration with SnMP did not reduce CoPP-induced 
Ho-1 expression (Supp Fig 4.10a) but did prevent the induction of F480 and Cd68 (Supp Fig 
4.10b-c) whilst only partially reversing the inhibition of Adipoq expression (Supp Fig 4.10d).  
These results confirm the major effects of CoPP are common across adipose tissues whilst also 
demonstrating subtle differences in the magnitude of these effects and the response to co-treatment 
with SnMP. 
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Fig 4. 7 - SnMP co-treatment ameliorates the effect of CoPP on inflammatory gene expression 
profiles in epididymal adipose tissue. Obese mice were maintained on a HFD and were 
administered CoPP (3 mg/Kg; 1 time/week) alone or in combination with SnMP (20 mg/Kg; 3 
times/week) or vehicle (veh) for 6 weeks such that all mice were treated 3 times/week. HO-1 (a) 
gene and (b) protein levels in epididymal adipose tissue. Expression of (c) Ferritin, (d) F480, (e) 
Cd68, (f) Cd11b, (g) Tnfα, (h) Mcp-1 and (i) Adipoq in epididymal adipose tissue. Correlations 
between Tnfα and (j) Ferritin or (k) Adipoq. (n ≥  7 for all groups). *p<0.05; **p<0.01; 
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***p<0.001; a – i one-way ANOVA with Tukey’s post hoc test; j – k two-way ANOVA with 
Bonferroni’s post hoc test. 
 
4.5.8 Co-treatment with SnMP does not prevent the effects of CoPP on hepatic 
steatosis 
Co-treatment with SnMP promoted a slight, but significant, increase in hepatic induction of Ho-1 
but this did not translate to an increase in hepatic HO-1 protein (Fig 4.8a & b).  The effects of 
CoPP and therefore co-administration of SnMP on hepatic Ferritin and inflammatory gene 
expression profiles were relatively modest and typically failed to reach statistical significance (Fig 
4.8c-g).  Our previous findings revealed the most striking hepatic effect of CoPP to be the 
reduction in steatosis, which correlated with change in body weight and insulin responsiveness.  
These effects were all maintained upon co-treatment with SnMP (Fig 4.8h-k).  Taken together with 
our findings from the first cohort, these observations suggest that CoPP may induce modest hepatic 
inflammation but this is not associated with the degree of hepatic steatosis.  
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Fig 4. 8 – Co-treatment with SnMP does not prevent the effect of CoPP on hepatic steatosis.  
Obese mice were maintained on a HFD and were administered CoPP (3 mg/Kg; 1 time/week) alone 
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or in combination with SnMP (20 mg/Kg; 3 times/week) or vehicle (veh) for 6 weeks such that all 
mice were treated 3 times/week. HO-1 (a) gene and (b) protein levels in liver. Expression of (c) 
Ferritin, (d) F480, (e) Cd68, (f) Cd11b, (g) Tnfα, and (h) Mcp-1. (i) Oil Red O stain and (j) 
quantitation of hepatic lipid accumulation. Correlations between (k) Δ body weight or (l) insulin 
responsiveness and hepatic steatosis. (n ≥ 7 for all groups). *p<0.05; **p<0.01; ***p<0.001; a – j 
one-way ANOVA with Tukey’s post hoc test; k – l two-way ANOVA with Bonferroni’s post hoc 
test. 
 
 
4.6 Discussion 
In the current report we aimed to characterise the effects of the widely-used HO-1 inducer CoPP on 
WAT and adiponectin in the context of a mouse model of diet-induced obesity.  Our results 
demonstrate that, at least under the experimental conditions employed, CoPP-treatment results in 
diverse, often counterintuitive effects and only some of these appear to be dependent on increased 
HO-1 activity based on sensitivity to co-treatment with SnMP.  Of particular interest, we found 
that CoPP administration increased the inflammatory gene signature in WAT and reduced Adipoq 
expression yet, consistent with other reports [217, 237, 241, 242, 272, 279, 306], increased 
circulating adiponectin levels.  Co-treatment with SnMP prevented the increase in inflammation 
(Fig 4.7), had no significant effect on Adipoq expression (Fig 4.7i) yet halved the effect of CoPP                                 
on circulating adiponectin (Fig 4.6c).  In addition, CoPP-treatment also prevented weight gain in 
obese mice and this correlated with improvements in insulin responsiveness, adipocyte size and 
hepatic steatosis, none of which were affected by SnMP co-treatment.  Taken together, these 
results demonstrate that CoPP promotes divergent effects that are both HO-1-dependent and 
independent.  Importantly, when considered alongside other reports [217, 237, 241, 242, 272, 279, 
306], they support a model whereby the CoPP-induced increase in circulating adiponectin is 
unlikely to reflect increased production from WAT but is more likely to be due to increased 
adiponectin production from other sites, possibly bone marrow adipose tissue (BMAT) [239, 243, 
304]. 
Numerous investigations in a variety of murine models of obesity have established that CoPP 
administration results in reduced weight gain and increased circulating adiponectin levels [217, 237, 
241, 242, 272, 279, 306].  Many of these studies also provide evidence to support a role for HO-1 
in these effects as they are typically prevented or blunted by co-treatment with SnMP [217, 237, 
241].  Perhaps surprisingly then, the major site(s) of action and molecular details of these effects 
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remain poorly understood as does the precise role of HO-1.  Indeed, reports involving genetic or 
pharmacological approaches to manipulate the ‘HO-1 axis’ provide results that highlight the 
complexity of the axis and the need for considered interpretation and subsequent integration of the 
findings [204, 281, 282]. 
In this context, given the absence of any compelling evidence to either prove or disprove a direct 
effect of HO-1 induction on adiponectin production from mature adipocytes we performed a series 
of investigations using CoPP, or hemin, that show that induction of HO-1 does not stimulate 
increased adiponectin production from mature human adipocytes [288].  These observations are in 
stark contrast to a number of studies that report that chronic induction of HO-1 during the process 
of adipogenesis results in increased adiponectin production [230, 238, 239, 243, 291].  In an 
attempt to reconcile these discordant findings we performed a comprehensive series of 
investigations to characterise the effects of chronic induction of HO-1 on adipogenesis and 
adiponectin production from human preadipocytes/adipocytes.  Consistent with the literature, we 
found induction of HO-1 with CoPP, or hemin, compromised adipogenesis in a dose-dependent 
manner.  However, under no conditions did we observe increased adiponectin expression or 
secretion (Yang et al, under review, SREP-16-40083).  Moreover, studies that aimed to 
characterise the mechanistic processes responsible for these effects, involving SnMP or HO-1 
knockdown, demonstrated these effects were independent of HO-1 activity and were more likely 
mediated by other targets, possibly downstream effectors of NRF2 (Yang et al, under review, 
SREP-16-40083). 
A fundamental difference between our investigations and studies that suggest a key role for HO-1 is 
the cell-type.  Whilst we used cells derived from subcutaneous WAT (either the SGBS cell strain or 
primary cells) studies that have reported a HO-1-dependent increase in adiponectin production have 
been performed almost exclusively in mesenchymal stem cells derived from bone marrow [230, 238, 
239, 243, 291].  Thus, it remains possible that the processes governing adiponectin production are 
distinct in these discrete cell types.  Indeed, evidence demonstrates that BMAT and, more 
specifically, adiponectin production from BMAT is regulated differently to that from classic WAT 
[304].  Carefully controlled studies investigating the effects of HO-1 induction on adiponectin 
production from preadipocytes/adipocytes derived from the different depots are required to 
investigate whether intrinsic differences between cell-types contribute to the differences described 
above. 
Notwithstanding the observed differences in the in vitro systems outlined above key fundamental 
differences are also apparent when considering the findings from in vivo models.  For example, in 
the current study we used a treatment regime used by others [217, 306] but made several contrasting 
observations.  Like others [217, 237, 241, 242, 272, 279, 306], we found that CoPP administration 
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prevented weight gain in HFD-induced obese mice.  However, this effect was not prevented by 
co-treatment with SnMP, implying HO-1-independence, whereas the effect was abolished or 
reduced by SnMP in studies of genetically (ob/ob mice) [217, 237] or HFD-induced [306] obese 
mice or rats [287].  The reasons for the differential sensitivity to SnMP is unclear.  One 
possibility is that the mechanism by which CoPP affects weight gain, and other parameters, in the 
context of obesity may differ over time.  Obesity is a progressive state with temporal alterations in 
stressors of specific cell-types and tissues, as evidenced by the dynamics of adipose tissue 
inflammation and development of ectopic lipid accumulation and insulin resistance [308, 312-314].  
Thus, it seems reasonable to consider that the mechanisms by which pharmacological agents such 
as CoPP, which are known to be pleiotropic rather than specific [204], may mediate similar effects 
by alternate mechanisms that are context-dependent. 
Given that reduced weight gain is a common effect of CoPP, or other HO-1 inducers such as heme 
[217, 237, 241, 242, 272, 279, 306], it is important that effects on weight are taken into account 
when considering related metabolic effects.  Surprisingly, this seldom appears to be the case.  In 
the current study we specifically explored whether the observed effects of CoPP correlated with its 
effects on weight.  Perhaps reassuringly, we found that adipocyte size, liver steatosis and insulin 
responsiveness all correlated with change in body weight during the 6 week intervention and that 
none of these effects were sensitive to SnMP.  Together, these findings argue that the metabolic 
improvements mediated by CoPP-treatment under these experimental conditions are all associated 
with the prevention in weight gain and are independent of HO-1 activity per se.  The mechanism(s) 
by which CoPP promotes a reduction in weight gain may include a reduction in food/energy intake, 
as reported here and elsewhere [220], and or an increase in metabolic rates [279], possibly via 
increased mitochondrial biogenesis and ‘browning’ of white preadipocytes/adipocytes [315].  With 
respect to the latter, we did not observe any increase in Ucp-1 expression, a marker of brown 
adipocytes, in epididymal or subcutaneous adipose tissue from CoPP-treated mice (Supp Fig 4.11a). 
Perhaps surprisingly, to the best of our knowledge, no study has described the effects of 
CoPP-treatment on WAT or adiponectin expression in this tissue.  Moreover, we found that 
CoPP-treatment promoted an increase in the inflammatory signature in WAT and that this was 
independent of obesity.  This effect was abolished by co-treatment with SnMP, which did not 
affect weight gain or insulin responsiveness, indicating that this inflammatory effect was dependent 
on HO-1 activity.  Whilst these findings are in stark contrast to observations made in BMAT [217, 
237, 241, 242, 272, 279, 306] they are supported by findings from genetic models [204, 281, 316].  
Evidence indicates that conditional deletion of HO-1 from macrophages is sufficient to ameliorate 
diet induced insulin resistance and adipose tissue inflammation [204].  Indeed, myeloid-specific 
haploinsufficiency of HO-1 was sufficient to reduce infiltration of macrophages into WAT [316].  
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Thus, we propose that CoPP elevates HO-1 activity in myeloid-derived cells and that this 
subsequently results in increased macrophage infiltration and inflammation in WAT.  We observed 
comparable, albeit more moderate, effects in liver and suggest that these are explained by a similar 
mechanism [204, 316].  The role of adipose tissue inflammation in the aetiology of insulin 
resistance is far from clear [308, 317] and our observations provide further evidence that adipose 
tissue inflammation does not correlate with changes in insulin sensitivity. 
Adipoq expression in both epididymal and subcutaneous WAT was reduced by CoPP-treatment.  
This contrasts with the findings in BMAT [230, 238, 239, 243, 291] highlighting additional 
differences.  Our correlation analyses suggest the reduction in Adipoq expression in WAT is 
associated with the increased WAT inflammation, which in turn correlated with Ferritin, a marker 
of increased HO-1 activity in WAT.   However, there was no correlation between Adipoq 
expression and Ferritin and the effect of SnMP on Adipoq expression was, at best, modest.  The 
underlying reasons for these discrepancies are currently obscure.  In contrast, it is clear that the 
changes in Adipoq expression in WAT do not reflect the changes in circulating adiponectin levels, 
which are increased by CoPP and are blunted by co-treatment with SnMP.  Whilst changes in 
Adipoq expression are not always reflected by similar changes in its secretion or the circulating 
levels, we are aware of no precedent where Adipoq expression is reduced (by 30-60%) and 
circulating levels are increased (by 30-50%) [252, 258].  Hence, we propose that adiponectin 
production from WAT is reduced following CoPP-treatment but this is not reflected in the 
circulating adiponectin levels due to opposite changes in adiponectin production from alternate sites.  
A body of evidence indicates that CoPP, or other HO-1 inducers, promotes adiponectin production 
from BMAT [230, 238, 239, 243, 291]. Moreover, increased adiponectin production from BMAT 
has been shown to underpin the increased circulating adiponectin levels reported following caloric 
restriction [304].  Thus, it seems reasonable to propose that the increase in circulating adiponectin 
levels are mediated by increased production from BMAT.  Future studies are required to 
investigate such a model and, if correct, elaborate the molecular mechanisms responsible for the 
divergent effects in the different adipose tissues. 
Intriguingly, in the current study the CoPP-mediated improvement in insulin responsiveness 
correlated with the change in weight but occurred in the absence of any enhancement in glucose 
tolerance. One possible explanation for these results would be if CoPP-treatment promoted a defect 
in insulin production. Whilst measurement of circulating insulin levels during the GTT failed to 
reveal such a defect (data not shown) it remains feasible that CoPP may result in increased islet 
inflammation, similar to the scenario described above in WAT, thereby compromising the ability of 
the insulin-producing β-cells to process precursor insulin efficiently, leading to secretion of 
immature, pro-insulin which has limited potency compared to mature insulin [321].  It may be 
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anticipated that the effects of CoPP on the ITT (insulin responsiveness) and GTT (glucose tolerance) 
would be enhanced if the tests were performed within the 24 h period post-CoPP administration, 
when food intake was significantly reduced although we, nor others [210, 217], have performed 
such investigations at this time point. 
In summary, in the present study we have shown that chronic administration of CoPP in obese mice 
promotes a number of divergent effects and that only some of these were dependent on HO-1 
activity.  CoPP increased circulating adiponectin levels, by a mechanism that was at least partly 
dependent on HO-1 activity, despite also promoting increased inflammation and reduced 
adiponectin expression in WAT.  Elaborating the underlying mechanisms may provide novel 
therapeutic strategies. 
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Supp Fig 4.9 – Effect of CoPP administration on gene expression profiles in subcutaneous 
adipose tissue. Obese mice were maintained on a HFD and treated weekly with CoPP (3 mg/Kg) 
for 6 weeks.  Expression of (a) Ho-1, (b) Adipoq and (c) F480 in subcutaneous adipose tissue after 
6 weeks.  n=12 for all groups; *p<0.05; **p<0.01; two-way ANOVA with Bonferroni’s post hoc 
test. 
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Supp Fig 4.10 - SnMP co-treatment ameliorates the effect of CoPP on inflammatory gene 
expression profiles in subcutaneous adipose tissue.  Obese mice were maintained on a HFD and 
were administered CoPP (3 mg/Kg; 1 time/week) alone or in combination with SnMP (20 mg/Kg; 3 
times/week) or vehicle (veh) for 6 weeks such that all mice were treated 3 times/week.  Expression 
of (a) Ho-1, (b) F480, (c) Cd68 and (d) Adipoq in subcutaneous adipose tissue.  (n ≥ 7 for all 
groups). *p<0.05; **p<0.01; ***p<0.001; one-way ANOVA with Tukey’s post hoc test. 
 
 
Supp Fig 4.11 – UCP1 gene expression and insulin levels. Obese mice were maintained on a 
HFD and were administered CoPP (3 mg/Kg; 1 time/week).  Expression of (a) Ucp1 in 
subcutaneous fat pad, (b) insulin levels in CoPP-treated HFD animals. 
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General Discussion 
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5.1 Overview 
The prevalence of obesity and metabolic and cardiovascular diseases has been growing at an 
alarming rate globally, and current therapies have brought limited benefits [322]. Thus, it is 
essential to develop new strategies to reduce effects of these diseases. Adiponectin is a beneficial 
adipokine with insulin-sensitising, anti-inflammatory and cardioprotective properties [58, 253, 254]. 
Hypoadiponectinemia is implicated in the aetiology of obesity-associated diseases making 
therapeutic strategies to increase adiponectin attractive [252]. Heme Oxygenase-1 is a rate-limiting 
enzyme that catalysts the degradation of heme into three by-products, carbon monoxide (CO), iron 
and biliverdin, which is subsequently converted to bilirubin [261]. In preclinical models, induction 
of HO-1 has been reported to increase circulating adiponectin levels, concomitant with a decrease in 
inflammatory cytokines, prompting the proposal of a “HO-1 – adiponectin axis” [217, 225, 227, 230, 
239, 241, 264-268]. However, contradictory findings showed that a classic transgenic approach to 
increased HO-1 in adipose tissue failed to reverse the HFD-induced decrease in adiponectin [281]. 
Work in this area reported by Jais et al. continues to put HO-1 center-stage in obesity and insulin 
resistance, but as a driver rather than a brake of obesity-associated inflammation [204]. In keeping 
with findings from the current study, they found no evidence of a major role for HO-1 in the 
adipocyte or muscle or pancreatic β-cells [204]. The aim of this thesis was to determine the 
underlying mechanisms and the relationship between HO-1, insulin sensitivity, adiposity, 
adiponectin and inflammation. Key findings are outlined below: 
1. Inducers of HO-1 acutely (24-48 h) increase HO-1 mRNA, protein and activity in mature 
adipocytes. 
2. Acute induction of HO-1 does not enhance or rescue adiponectin production in healthy or 
TNFα-treated mature adipocytes. 
3. Acute induction of HO-1 does not ameliorate TNFα-stimulated expression and secretion of 
pro-inflammatory adipocytokines in mature adipocytes. 
4. Chronic CoPP or hemin treatment (throughout differentiation) increase HO-1 mRNA and 
protein, as well as other Nrf2 related gene expressions in human preadipocytes. 
5. Chronic CoPP or hemin treatment decrease lipid accumulation, interferes with adipogenesis, 
decreases adiponectin production and increases inflammatory tone in human preadipocytes 
6. Co-treatment with a HO-1 inhibitor (SnMP) or HO-1 siRNA failed to reverse the effects of 
chronic CoPP or hemin treatment in human preadipocytes. 
7. CoPP-treatment of obese mice result in decreased food intake, body weight gain and 
adipocyte size as well as enhanced insulin sensitivity and attenuated liver steatosis. 
8. Obese CoPP-treated mice display increased adipose tissue inflammation and reduced 
adiponectin expression; however, circulating adiponectin levels are increased. 
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9. Co-administration of a HO-1 inhibitor SnMP in obese mice ameliorated CoPP effects on 
adipose tissue inflammation and blunted CoPP effects on circulating adiponectin, while other 
parameters were unchanged.   
 
5.2 General discussion and further directions 
During the course of this research, our findings do not support a direct “HO-1 – adiponectin axis” in 
WAT. They also suggest that WAT is unlikely to be involved in the systemic beneficial effects of 
CoPP or hemin treatment.  
In the earlier sections of this thesis, we aimed to establish the existence of direct “HO-1 – 
adiponectin axis”. We treated mature adipocytes with widely-used HO-1 inducers CoPP or hemin 
acutely (24-48 h). We expected an increase in adiponectin production in this experiment. However, 
our results revealed that HO-1 induction has no direct effect on adiponectin production in human 
adipocytes in vitro.  In addition, induction of HO-1 did not ameliorate the effects of TNFα on 
adiponectin production or inflammatory tone in human adipocytes. These findings do not support a 
direct “HO-1 – adiponectin axis.” Instead, our results indicated that the association between HO-1 
inductions and increased circulating adiponectin levels are most likely to be a chronic or indirect 
effect.  One possibility is that chronic HO-1 inductionmay increase adiponectin indirectly by 
altering differentiation of preadipocytes. Consistent with this hypothesis, evidence in the literature 
shows that chronic CoPP treatment throughout the process of differentiation increases adiponectin 
production, albeit it reduces adipogenesis [238, 242]. It seems unlikely that inhibition of 
adipogenesis would result in increased adiponectin production. However, we previously reported 
that adiponectin secretion was highest in immature adipocytes [278]. Thus, it remains possible that 
chronic CoPP treatment may arrest differentiation at a stage where adiponectin production is higher 
than in the mature adipocytes.  To find out whether chronic CoPP or hemin treatment, across 
appropriate dose-response curves, could increase adiponectin production at a “specific 
concentration,” we extended these studies to characterize the dose-dependent effects of chronic 
CoPP and hemin treatment throughout differentiation of human preadipocytes. To our surprise, 
results showed that chronic CoPP and hemin treatment inhibited differentiation in a dose-dependent 
manner, but under no condition was adiponectin production increased. Rather more surprising is 
that co-treatment with a HO-1 activity inhibitor (SnMP) or HO-1 siRNA failed to reverse these 
effects. These results strongly suggested that the effects of chronic CoPP and hemin administration 
in adipocytes are HO-1-independent.  
The above findings indicat that induction of HO-1 fails to promote adiponectin production in human 
adipocytes in vitro. In contrast, the majority of preclinical studies suggest that induction of HO-1 
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increases adiponectin production and improves metabolic status via a “HO-1 – adiponectin axis” 
[217, 225, 227, 230, 239, 241, 264-268]. To test this ourselves, we performed a series of 
experiments in preclinical models. We found that CoPP administration to obese mice significantly 
decreased body weight gain, and this change is significantly correlated with changes in adipocyte 
size, and liver steatosis. The ITT significantly improves in obese mice following CoPP treatment, 
but there is no significant change in GTT, which suggests improvements in muscle insulin 
sensitivity but not necessarily improvements in the liver. Moreover, we found that CoPP-treatment 
promotes a range of divergent effects on adipose tissue and adiponectin, particularly in obese mice 
(Table 5.1). One possibility is that the decrease in adiponectin gene expression in adipose tissue that 
occurs concomitant with an increase in circulating adiponectin levels may reflect effects of CoPP on 
circulating adiponectin via direct effects on other tissues. Indeed, other studies showing CoPP 
administration increases adiponectin are mainly from studies involving BMSCs treated with CoPP 
[238, 242, 243, 294] or EET-agonists [230, 291, 294]. The fundamental difference between the 
experiments is the use of cells from different origins. Thus, it is tempting to speculate that 
adiponectin production from cells derived from BMSCs may be regulated differently than in human 
preadipocytes derived from adipose tissues. Indeed, and consistent with this, it has been reported 
that caloric restriction increased adiponectin production from bone marrow adipose tissue but not 
white adipose tissue which supports our proposal [304]. Based on these observations, we propose 
that CoPP does mediate the increase in circulating adiponectin levels via a mechanism that is at 
least partly HO-1 dependent, and may involve induction of adiponectin production from BMAT. 
However, further studies are required to investigate such a model. 
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Table 5.1 – Effect of CoPP or hemin in obese mice. 
UD-Undetermined 
 
Treatment of obese mice with hemin did not result in changes in body weight gain, liver steatosis or 
insulin responsiveness, which further support the hypothesis that the phenotype induced by CoPP 
administration is HO-1 activity independent (Table 5.1). Moreover, CoPP administration in obese 
mice significantly increased inflammatory gene expression and decreased adiponectin gene 
expression in WAT, which was slightly ameliorated by SnMP treatment (Table 5.2). Hemin 
treatments showed a similar pattern, but moderate effects on WAT, which suggested that these 
effects were, at least partly, HO-1 activity dependent. Thus, the in vivo results argue against a 
positive effect of HO-1 activity on adiponectin production in WAT but do confirm that CoPP 
increases circulating adiponectin levels. This contrasts with the in vitro results that argue against the 
“HO-1 – adiponectin axis,” which may due to the fact that different cell types have different 
response to CoPP. The hepatic effects of both CoPP and SnMP are relatively modest when 
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compared to those in adipose tissue. The underlying mechanisms remain unclear but may reflect a 
greater impact on influx of circulating inflammatory cells in adipose tissue (via direct effects on the 
inflammatory cells) than liver. 
 
   
Table 5.2 – Effects of CoPP and SnMP in obese mice. 
UD-Undetermined 
 
 
It is well established that CoPP induces HO-1 by modulating the transcriptional repressors and 
transcription factors, the downregulation of BACH1 and upregulation of NRF2 [275, 291, 297, 298]. 
Thus, CoPP is not a direct HO-1 specific inducer. In in vitro experiments, we found that the NQO1 
and GCLM gene expressions were increased by SnMP or HO-1 siRNA treatment, which suggests 
that NRF2 activity was increased by SnMP or HO-1 siRNA treatment. Considering the effects of 
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CoPP and hemin were not reversed by SnMP or HO-1 siRNA treatment, it is possible that HO-1 is 
not responsible for the effects of CoPP or hemin in human preadipocytes. These findings suggest 
that the chronic treatment with CoPP or hemin potentially inhibits adipogenesis and adiponectin 
production by a HO-1-independent mechanism that may be downstream of NRF2. However, our 
results contradict the literatures that support “HO-1 – adiponectin axis.”  
Collectively, in vitro studies demonstrated that CoPP treatment does not have any beneficial effect 
on adipocytes and does not support a direct “HO-1 – adiponectin axis” in WAT. In vivo studies 
showed that CoPP increased circulating adiponectin levels, by a mechanism that was at least partly 
dependent on HO-1 activity, despite also promoting increased inflammation and reduced 
adiponectin expression in WAT. Taken together with the current literature, these results suggest that 
BMAT, not WAT, plays an important role in the effect of HO-1 induction on adiponectin production. 
 
5.3 Conclusions 
Increasing in circulating adiponectin levels is recognized as an attractive potential target for the 
treatment of metabolic disorders. Nevertheless, current therapeutic strategies are not suitable due to 
a series of side effects. Thus it is essential to develop other therapeutic strategies. Despite numerous 
studies describing the existence of a HO-1-adiponectin axis, there is no direct evidence showing 
that HO-1 directly induces adiponectin production. The first aim of this study was to investigates 
whether HO-1 induces adiponectin production directly in vitro. Secondly, we investigate whether 
adipocytes are involved in the systemic beneficial effects of CoPP and hemin treatment. Further, we 
utilized a preclinical mouse model to investigate whether the beneficial effects of HO-1 induction 
are, at least partly, dependent on adiponectin. In this project we demonstrated (i) HO-1 induction via 
CoPP and hemin treatment have no direct effect on adiponectin production in mature adipocytes, (ii) 
Chronic HO-1 induction via CoPP and hemin treatment compromises adipogenesis in a manner 
which appears incompatible with enhanced adipocyte function and reduces adiponectin production 
and (iii) Chronic CoPP administration in obese mice promotes a number of divergent effects, only 
some of which were dependent on HO-1 activity. Although further studies are required to determine 
the mechanism for improving metabolic status by CoPP treatment, current studies established that 
CoPP treatment offer several benefits in the preclinical models although the majority of them are 
HO-1-independent. This work provides a foundation for future studies so that CoPP may become a 
new therapeutic strategy for metabolic disorders such as type 2 diabetes and CVD. 
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5.4 Further directions 
This thesis characterized the relationship between HO-1 and adiponectin, and it has disproved a main 
postulate in the field that shows a HO1-adiponectin axis. We performed a series of experiments to 
determine the effects of HO-1 agonists in mature adipocytes, differentiating adipocytes, and in an in 
vivo model. We found all three methods support the same conclusion. It is obvious that our results 
contradict previous research. Therefore, further studies are necessary. First of all, the reason that 
CoPP treatment increases adiponectin in MSCs but not human adipocytes is not clear and it is 
important to find out the reasons that different cell types have different response to CoPP. Secondly, in 
our previous reports, we found that CoPP and hemin treatments inhibit adipogenesis and decreases 
adipogenesis markers, but none of these effects were due to HO-1. We also found that CoPP and 
hemin are not specific inducers of HO-1, but they do induces other NRF2 related genes. Therefore, 
what role NRF2 plays in this system requires further investigation.  
In in vivo study, we found there is a significant decrease in food intake in CoPP-treated obese mice 
and other parameters were correlated with body weight reduction due to food intake decrease. 
Whether all of these changes were due to body weight reduction can be verified by feeding a group of 
mice the same amount of food eaten by CoPP-treated mice and measuring those parameters. In 
addition, we found circulating adiponectin levels were increased but adiponectin gene expression in 
WAT were decreased. Therefore, it is important to discover how circulating adiponectin levels 
increase under CoPP treatment in future studies. 
 
 
 
Mengliu Yang 
118 
 
 
Supp Fig 5.1 – Hemin administration in mice. Lean (L) and obese (O) mice were administered 
hemin (20 mg/Kg; 3 time/week) or vehicle (veh) for 6 weeks such that all mice were treated 3 
times/week. (A) Cumulative energy intake over the first 9 days of treatment in lean and obese mice 
(n=2). (B) Change in body weight after 6 weeks of treatment with or without hemin. GTT and ITT 
in (C) lean and (D) obese mice after 5 weeks of treatment (n = 8 for all groups). Circulating levels 
of (E) total and (F) HMW adiponectin after 6 weeks of treatment (n = 8 for all groups). *p<0.05; 
two-way ANOVA with a Bonferroni post hoc test. 
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Supp Fig 5.2 - Divergent effects of hemin on inflammatory and adiponectin gene expression 
profiles in epididymal adipose tissue. Lean (L) and obese (O) mice were administered hemin (20 
mg/Kg; 3 time/week) or vehicle (veh) for 6 weeks such that all mice were treated 3 times/week. 
HO-1 (A) gene and (B) protein levels in epididymal adipose tissue from lean and obese mice. 
Expression of (C) Nqo1, (D) Gclm, (E) Adipoq, (F) Tnfα, (G) F480, (H) Cd68, (I) Cd11b and (J) 
Mcp-1 in epididymal adipose tissue from lean and obese mice (n≥8 for all groups). *p<0.05; 
**p<0.01; ***p<0.001; two-way ANOVA with a Bonferroni post hoc test. 
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Supp Fig 5.3 - The effect of hemin on inflammatory gene expression profiles in subcutaneous 
adipose tissue.  Lean (L) and obese (O) mice were administered hemin (20 mg/Kg; 3 time/week) 
or vehicle (veh) for 6 weeks such that all mice were treated 3 times/week.   Expression of (A) 
Ho-1, (B) Adipoq and (C) F480 in subcutaneous adipose tissue.  (n = 8 for all groups). ***p<0.001; 
one-way ANOVA with Tukey’s post hoc test. 
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